<?xml version="1.0" ?>
<!DOCTYPE pmc-articleset PUBLIC "-//NLM//DTD ARTICLE SET 2.0//EN" "https://dtd.nlm.nih.gov/ncbi/pmc/articleset/nlm-articleset-2.0.dtd">
<pmc-articleset><article xmlns:xlink="http://www.w3.org/1999/xlink" article-type="research-article">
  <?properties open_access?>
  <front>
    <journal-meta>
      <journal-id journal-id-type="nlm-ta">Purinergic Signal</journal-id>
      <journal-title>Purinergic Signalling</journal-title>
      <issn pub-type="ppub">1573-9538</issn>
      <issn pub-type="epub">1573-9546</issn>
      <publisher>
        <publisher-name>Springer Netherlands</publisher-name>
        <publisher-loc>Dordrecht</publisher-loc>
      </publisher>
    </journal-meta>
    <article-meta>
      <article-id pub-id-type="pmid">18404453</article-id>
      <article-id pub-id-type="pmc">2072917</article-id>
      <article-id pub-id-type="publisher-id">9073</article-id>
      <article-id pub-id-type="doi">10.1007/s11302-007-9073-z</article-id>
      <article-categories>
        <subj-group subj-group-type="heading">
          <subject>Original Paper</subject>
        </subj-group>
      </article-categories>
      <title-group>
        <article-title>MPP<sup>+</sup>-induced cytotoxicity in neuroblastoma cells: Antagonism and reversal by guanosine</article-title>
      </title-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Pettifer</surname>
            <given-names>Kathleen M.</given-names>
          </name>
          <xref ref-type="aff" rid="Aff1">1</xref>
        </contrib>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Jiang</surname>
            <given-names>Shucui</given-names>
          </name>
          <xref ref-type="aff" rid="Aff2">2</xref>
        </contrib>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Bau</surname>
            <given-names>Christian</given-names>
          </name>
          <xref ref-type="aff" rid="Aff1">1</xref>
        </contrib>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Ballerini</surname>
            <given-names>Patrizia</given-names>
          </name>
          <xref ref-type="aff" rid="Aff3">3</xref>
        </contrib>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>D&#x2019;Alimonte</surname>
            <given-names>Iolanda</given-names>
          </name>
          <xref ref-type="aff" rid="Aff3">3</xref>
        </contrib>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Werstiuk</surname>
            <given-names>Eva S.</given-names>
          </name>
          <xref ref-type="aff" rid="Aff1">1</xref>
        </contrib>
        <contrib contrib-type="author" corresp="yes">
          <name name-style="western">
            <surname>Rathbone</surname>
            <given-names>Michel P.</given-names>
          </name>
          <address>
            <phone>+1-905-5748630</phone>
            <fax>+1-905-38833958</fax>
            <email>mrathbon@mcmaster.ca</email>
          </address>
          <xref ref-type="aff" rid="Aff1">1</xref>
          <xref ref-type="aff" rid="Aff4">4</xref>
        </contrib>
        <aff id="Aff1"><label>1</label>Departments of Medicine, McMaster University, Hamilton, ON Canada </aff>
        <aff id="Aff2"><label>2</label>Departments of Surgery, McMaster University, Hamilton, ON Canada </aff>
        <aff id="Aff3"><label>3</label>Department of Biomedical Sciences, School of Medicine, University of Chieti, Chieti, Italy </aff>
        <aff id="Aff4"><label>4</label>Department of Medicine, McMaster University, Health Sciences Center, 4N 71B, Hamilton, ON L8N 3Z5 Canada </aff>
      </contrib-group>
      <pub-date pub-type="epub">
        <day>3</day>
        <month>10</month>
        <year>2007</year>
      </pub-date>
      <pub-date pub-type="ppub">
        <month>9</month>
        <year>2007</year>
      </pub-date>
      <volume>3</volume>
      <issue>4</issue>
      <fpage>399</fpage>
      <lpage>409</lpage>
      <history>
        <date date-type="received">
          <day>22</day>
          <month>6</month>
          <year>2007</year>
        </date>
        <date date-type="accepted">
          <day>9</day>
          <month>8</month>
          <year>2007</year>
        </date>
      </history>
      <permissions>
        <copyright-statement>&#xA9; Springer Science + Business Media B.V. 2007</copyright-statement>
      </permissions>
      <abstract>
        <p>Guanosine exerts neuroprotective effects in the central nervous system. Apoptosis, a morphological form of programmed cell death, is implicated in the pathophysiology of Parkinson&#x2019;s disease (PD). MPP<sup>+</sup>, a dopaminergic neurotoxin, produces in vivo and in vitro cellular changes characteristic of PD, such as cytotoxicity, resulting in apoptosis. Undifferentiated human SH-SY5Y neuroblastoma cells had been used as an in vitro model of Parkinson&#x2019;s disease. We investigated if extracellular guanosine affected MPP<sup>+</sup>-induced cytotoxicity and examined the molecular mechanisms mediating its effects. Exposure of neuroblastoma cells to MPP<sup>+</sup> (10&#xA0;&#x3BC;M&#x2013;5&#xA0;mM for 24&#x2013;72&#xA0;h) induced DNA fragmentation in a time-dependent manner (<italic>p</italic>&#x2009;&lt;&#x2009;0.05). Administration of guanosine (100&#xA0;&#x3BC;M) <italic>before, concomitantly with</italic> or, importantly, <italic>after</italic> the addition of MPP<sup>+</sup> abolished MPP<sup>+</sup>-induced DNA fragmentation. Addition of MPP<sup>+</sup> (500&#xA0;&#x3BC;M) to cells increased caspase-3 activity over 72&#xA0;h (<italic>p</italic>&#x2009;&lt;&#x2009;0.05), and this was abolished by pre- or co-treatment with guanosine. Exposure of cells to pertussis toxin prior to MPP<sup>+</sup> eliminated the anti-apoptotic effect of guanosine, indicating that this effect is dependent on a Gi protein-coupled receptor, most likely the putative guanosine receptor. The protection by guanosine was also abolished by the selective inhibitor of the enzyme PI-3-K/Akt/PKB (LY294002), confirming that this pathway plays a decisive role in this effect of guanosine. Neither MPP<sup>+</sup> nor guanosine had any significant effect on &#x3B1;-synuclein expression. Thus, guanosine antagonizes and reverses MPP<sup>+</sup>-induced cytotoxicity of neuroblastoma cells via activation of the cell survival pathway, PI-3-K/Akt/PKB. Our results suggest that guanosine may be an effective pharmacological intervention in PD.</p>
      </abstract>
      <kwd-group>
        <title>Keywords</title>
        <kwd>Apoptosis</kwd>
        <kwd>Caspase-3</kwd>
        <kwd>Cell survival</kwd>
        <kwd>Cytotoxicity</kwd>
        <kwd>DNA fragmentation</kwd>
        <kwd>Guanosine</kwd>
        <kwd>1-methyl&#x2013;4-phenyl-pyridinium (MPP<sup>+</sup>)</kwd>
        <kwd>Parkinson&#x2019;s disease</kwd>
        <kwd>SH-SY5Y human neuroblastoma cells</kwd>
      </kwd-group>
      <custom-meta-wrap>
        <custom-meta>
          <meta-name>issue-copyright-statement</meta-name>
          <meta-value>&#xA9; Springer Science+Business Media B.V. 2007</meta-value>
        </custom-meta>
      </custom-meta-wrap>
    </article-meta>
  </front>
  <body>
    <sec id="Sec1" sec-type="introduction">
      <title>Introduction</title>
      <p>Parkinson&#x2019;s disease (PD) is a progressive neurodegenerative disorder caused primarily by selective degeneration of dopaminergic neurons in the substantia nigra pars compacta [<xref ref-type="bibr" rid="CR1">1</xref>, <xref ref-type="bibr" rid="CR2">2</xref>]. Apoptosis, a morphological form of programmed cell death [<xref ref-type="bibr" rid="CR3">3</xref>], has been implicated in the pathophysiology of PD [<xref ref-type="bibr" rid="CR4">4</xref>&#x2013;<xref ref-type="bibr" rid="CR6">6</xref>]. The biochemical pathways that mediate apoptosis may be initiated by extrinsic (e.g. activation of the death receptors) or intrinsic factors (e.g. mitochondrial insult) [<xref ref-type="bibr" rid="CR7">7</xref>] and result in the activation of a set of cysteine-dependent aspartyl proteases (caspases) [<xref ref-type="bibr" rid="CR8">8</xref>]. Both apoptotic pathways stimulate the effector enzyme, caspase-3 [<xref ref-type="bibr" rid="CR7">7</xref>, <xref ref-type="bibr" rid="CR9">9</xref>, <xref ref-type="bibr" rid="CR10">10</xref>], which in turn activates a specific nuclear DNAse that degrades DNA into 200 base pair oligonucleosomal fragments, a hallmark of apoptosis [<xref ref-type="bibr" rid="CR11">11</xref>, <xref ref-type="bibr" rid="CR12">12</xref>]. Apoptosis-related alterations have been reported in the dopaminergic brain regions in post-mortem tissues of PD patients, including increased caspase-3 activity in the substantia nigra [<xref ref-type="bibr" rid="CR13">13</xref>, <xref ref-type="bibr" rid="CR14">14</xref>], and elevated immunoreactivity of the pro-apoptotic protein, Bax [<xref ref-type="bibr" rid="CR15">15</xref>], indicating that apoptosis may play a role in the pathophysiology of PD.</p>
      <p>The neurotoxin 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) has been used extensively to study PD [<xref ref-type="bibr" rid="CR16">16</xref>, <xref ref-type="bibr" rid="CR17">17</xref>]. MPTP selectively targets and damages the dopaminergic neurons causing parkinsonism in humans and other primates [<xref ref-type="bibr" rid="CR18">18</xref>, <xref ref-type="bibr" rid="CR19">19</xref>]. MPTP readily crosses the blood-brain barrier and is converted into the active metabolite, 1-methyl-4-phenyl pyridinium (MPP<sup>+</sup>) [<xref ref-type="bibr" rid="CR17">17</xref>]. MPP<sup>+</sup> is taken up by the dopaminergic neurons and accumulates in the mitochondria, where it inhibits complex I of the electron transport chain and ultimately causes neuronal cell death [<xref ref-type="bibr" rid="CR5">5</xref>]. The mechanisms of MPP<sup>+</sup>-induced cytotoxicity most likely involve oxidative stress [<xref ref-type="bibr" rid="CR20">20</xref>]. Several groups reported that treatment of mice with MPTP induces a Parkinson-like syndrome [<xref ref-type="bibr" rid="CR16">16</xref>], accompanied by apoptosis of the dopaminergic neurons in the substantia nigra [<xref ref-type="bibr" rid="CR21">21</xref>] and up-regulation of &#x3B1;-synuclein, a pre-synaptic protein, which plays an important role in PD pathogenesis [<xref ref-type="bibr" rid="CR22">22</xref>]. In vitro studies using human SH-SY5Y neuroblastoma cells have produced comparable results [<xref ref-type="bibr" rid="CR23">23</xref>, <xref ref-type="bibr" rid="CR24">24</xref>]. Exposure of these cells to MPP<sup>+</sup> led to fragmentation of nuclear DNA [<xref ref-type="bibr" rid="CR25">25</xref>], activation of caspase-3 [<xref ref-type="bibr" rid="CR23">23</xref>, <xref ref-type="bibr" rid="CR26">26</xref>] and to up-regulation of &#x3B1;-synuclein [<xref ref-type="bibr" rid="CR27">27</xref>&#x2013;<xref ref-type="bibr" rid="CR29">29</xref>]. In cultured SH-SY5Y cells dopamine-dependent cytotoxicity was enhanced by the accumulation of &#x3B1;-synuclein [<xref ref-type="bibr" rid="CR30">30</xref>]. Therefore, targeting the molecular pathways activated during apoptosis may lead to novel treatment strategies for PD [<xref ref-type="bibr" rid="CR5">5</xref>, <xref ref-type="bibr" rid="CR31">31</xref>].</p>
      <p>Guanosine and other non-adenine-based purines exert neuroprotective effects in the central nervous system [<xref ref-type="bibr" rid="CR32">32</xref>]. In vitro guanosine also protects rat astrocytes from staurosporine-induced apoptosis [<xref ref-type="bibr" rid="CR33">33</xref>] and SH-SY5Y cells from &#x3B2;-amyloid-induced apoptosis [<xref ref-type="bibr" rid="CR34">34</xref>]. In both cases, the anti-apoptotic effect of guanosine was mediated by stimulation of the phosphatidylinositol-3-kinase (PI-3-K)/Akt/protein kinase B (PKB) and mitogen-activated protein kinase (MAPK) cell survival pathways [<xref ref-type="bibr" rid="CR33">33</xref>, <xref ref-type="bibr" rid="CR34">34</xref>]. These pathways were activated via the pertussis toxin-sensitive Gi protein-coupled putative guanosine receptor that we have recently characterized pharmacologically [<xref ref-type="bibr" rid="CR35">35</xref>&#x2013;<xref ref-type="bibr" rid="CR37">37</xref>].</p>
      <p>In PD, symptoms appear only after the majority of the dopaminergic neurons in the substantia nigra pars compacta have degenerated, so putative neuroprotective drugs for PD should be tested in models in which the neurodegenerative process is already underway [<xref ref-type="bibr" rid="CR38">38</xref>]. Therefore, we examined the effects of guanosine on MPP<sup>+</sup>-induced caspase-3 activation and DNA fragmentation in SH-SY5Y human neuroblastoma cells not only when it was added prior to, or at the same time as MPP<sup>+</sup>, but also when it was added to the cultures up to 48 h <italic>after</italic> MPP<sup>+</sup> treatment, when the pro-apoptotic pathways were already activated. We also studied the molecular mechanisms that mediate the neuroprotective effects of guanosine.</p>
    </sec>
    <sec id="Sec2" sec-type="materials|methods">
      <title>Materials and methods</title>
      <sec id="Sec3">
        <title>Tissue culture and treatment of human SH-SY5Y neuroblastoma cells</title>
        <p>Human SH-SY5Y neuroblastoma cells (ATCC, Manassas, VA, USA) were cultured using 45% minimum essential medium, 45% F12 Hamilton&#x2019;s medium supplemented with 10% fetal bovine serum (FBS), 100&#xA0;U/ml of penicillin and 100&#xA0;U/ml of streptomycin at a pH of 7.4 (all from Invitrogen, Burlington, ON, Canada). Culture medium was changed every 3&#x2013;4&#xA0;days, and cells were maintained in a humidified 5% CO<sub>2</sub> atmosphere at 37&#xB0;C and subcultured at a ratio of 1:20 every 7&#x2013;10&#xA0;days. Culture medium was changed to 1% FBS for 24&#xA0;h before the start of each experiments. All experiments were performed using 70&#x2013;80% confluent cultures.</p>
        <p>Apoptosis was induced by adding MPP<sup>+</sup> (Sigma-Aldrich) to SH-SY5Y neuroblastoma cells, using a fresh stock solution of MPP<sup>+</sup> (10&#xA0;mM in reverse osmosis purified H<sub>2</sub>O). In all experiments, guanosine (Sigma-Aldrich) was dissolved in 0.1&#xA0;M NaOH and added to the culture medium at a final concentration of 0.001&#xA0;M NaOH. Some cells (control) were exposed to 0.001&#xA0;M NaOH. In experiments in which the protective effect of guanosine was tested, guanosine (100&#xA0;&#x3BC;M) was added to SH-SY5Y neuroblastoma cells either: 1&#xA0;h prior to the administration of MPP<sup>+</sup> (<italic>pre-treatment</italic>), or at the same time as MPP<sup>+</sup> (<italic>co-treatment)</italic> or 24 or 48&#xA0;h after the addition of MPP<sup>+</sup><italic>(post-treatment</italic> at 24&#xA0;h, or post-treatment at 48&#xA0;h, respectively; Fig.&#xA0;<xref rid="Fig1" ref-type="fig">1</xref>). Guanosine and MPP<sup>+</sup> remained in the culture medium for the duration of the experiment (24, 48 or 72&#xA0;h). In the first <italic>post-treatment</italic> experimental group at 24&#xA0;h, cells were exposed to MPP<sup>+</sup> for 24&#xA0;h, followed by MPP<sup>+</sup> plus guanosine for an additional 24&#xA0;h (Fig.&#xA0;<xref rid="Fig1" ref-type="fig">1</xref>). In the second <italic>post-treatment</italic> experimental group at 48&#xA0;h, cells were treated with MPP<sup>+</sup> for 48&#xA0;h, followed by MPP<sup>+</sup> plus guanosine for an additional 24&#xA0;h (Fig.&#xA0;<xref rid="Fig1" ref-type="fig">1</xref>).
<fig id="Fig1"><label>Fig.&#xA0;1</label><caption><p>Experimental design for guanosine post-treatment of SH-SY5Y neuroblastoma cells added at 24&#xA0;or 48&#xA0;h after MPP<sup>+</sup>. SH-SY5Y neuroblastoma cells were exposed to either vehicle, or guanosine (100&#xA0;&#x3BC;M) or MPP<sup>+</sup> (500&#xA0;&#x3BC;M) for various times. For <italic>post-treatment</italic> experiments with guanosine at 24&#xA0;h, cells were exposed to MPP<sup>+</sup> for 24&#xA0;h, followed by MPP<sup>+</sup> plus guanosine for an additional 24&#xA0;h (total MPP<sup>+</sup> exposure = 48&#xA0;h). For <italic>post-treatment</italic> experiments with guanosine at 48&#xA0;h, cells were exposed to MPP<sup>+</sup> for 48&#xA0;h followed by MPP<sup>+</sup> plus guanosine for a further 24&#xA0;h (total MPP<sup>+</sup> exposure = 72&#xA0;h). Once added, guanosine and MPP<sup>+</sup> remained in the culture medium for the duration of the experiment. DNA fragmentation, or caspase-3 activity, was determined at 24, 48 or 72&#xA0;h as described in the &#x201C;<xref rid="Sec2" ref-type="sec">Materials and methods</xref>&#x201D; section</p></caption><graphic position="anchor" xlink:href="11302_2007_9073_Fig1_HTML" id="MO1"/></fig></p>
        <p>In experiments in which enzyme inhibitors were tested, SH-SY5Y cells were pre-treated with various agents for 20&#xA0;min prior to the addition of guanosine. These treatments included: the potent and selective inhibitor of PI-3-K, [2-(4-morpholinyl)-8-phenyl-1(4<italic>H</italic>)-benzopyran-4-1-hydrochloride] (LY294002; IC<sub>50</sub>&#x2009;=&#x2009;1.4&#xA0;&#x3BC;M; Sigma), or the selective inhibitor of MAP kinase kinase (MEK), [2-(2-amino-3-methoxyphenyl)-4<italic>H</italic>-1-benzopyran-4-1] (PD98059; IC<sub>50</sub>&#x2009;=&#x2009;2&#xA0;&#x3BC;M; Sigma). In experiments using the ADP-ribosylating factor of the inhibitory guanosine nucleotide binding protein (Gi), pertussis toxin [PTX, 200&#xA0;ng/ml; in 50% glycerol, 0.5&#xA0;M NaCl, and 0.05&#xA0;M Tris-glycine (pH 7.5); Sigma] was added overnight (16&#xA0;h). LY294002 and PD98059 were dissolved in and added to the culture medium at a final concentration of 0.01% dimethyl sulfoxide (DMSO).</p>
      </sec>
      <sec id="Sec4">
        <title>Evaluation of cell death and DNA fragmentation</title>
        <p>In initial experiments, cell death was determined using acridine orange-ethidium bromide (AO-EB, Sigma-Aldrich) staining. Cells were seeded onto 6-well plates (diameter 10&#xA0;mm; 2.5&#x2009;&#xD7;&#x2009;10<sup>4</sup> cells/well) and exposed to MPP<sup>+</sup>. After 24, 48 or 72&#xA0;h, cells were washed three times with phosphate-buffered saline (PBS) and AO-EB solution (6&#xA0;&#x3BC;M/ml) was added to the wells. Cells were examined using a fluorescence microscope (Nikon, Tokyo, Japan). The number of fragmented nuclei and/or condensed chromatin was determined by counting &gt;200 cells. The percentage of apoptotic cells is defined as: (total number of cells with apoptotic nuclei/total number of cells) &#xD7; 100.</p>
        <p>In subsequent experiments, DNA fragmentation was evaluated by the oligonucleosomal ELISA (Cell Death Detection ELISA<sup>PLUS</sup>; Roche Diagnostics, Laval, QC, Canada) and carried out according to the manufacturer&#x2019;s instructions. This assay measures the amount of oligonucleosomal fragments and is a marker of apoptosis [<xref ref-type="bibr" rid="CR39">39</xref>]. Cells were exposed to MPP<sup>+</sup> alone, or in combination with guanosine or pre-treated with the various inhibitors as described above. Following various treatments, cells were isolated for analysis of DNA fragmentation as described by Pettifer et al. [<xref ref-type="bibr" rid="CR34">34</xref>]. For the oligonucleosomal ELISA, 10,000 viable cells/treatment were lysed and centrifuged (200&#xA0;<italic>g</italic> for 10&#xA0;min) to isolate fragmented oligonucleosomal DNA. The cytosolic fractions of cell lysates were transferred into streptavidin-coated microplate wells, and a mixture of biotin-linked anti-histone antibody and peroxidase-linked anti-DNA antibody was added and incubated for 2&#xA0;h at room temperature. Plates were washed with incubation buffer to remove the unfixed anti-DNA antibody and the peroxidase activity was determined spectrophotometrically with 2,2&#x2032;-azino-bis[3-ethylbenzthiazoline-6-sulfonic acid] (ABTS) as the substrate (absorbance of 405&#xA0;nm). The amount of DNA fragmentation is expressed as a percentage of the positive control provided with the kit.</p>
      </sec>
      <sec id="Sec5">
        <title>Determination of caspase-3 activity</title>
        <p>Caspase-3 activity was determined using the caspase-3 colourimetric assay (Sigma-Aldrich). Cells were exposed to different treatments as described above; then cells were isolated, re-suspended in 100&#xA0;&#x3BC;l/10<sup>7</sup> cells of lysis buffer (50&#xA0;mM 4-(2-hydroxyethyl)-1-piperazineethanesulfonic acid (HEPES), pH 7.4, 5&#xA0;mM 3[(3-cholamidopropyl) dimethylammonio]-propanesulfonic acid (CHAPS), 5&#xA0;mM dithiothreitol (DTT)) and incubated on ice for 20&#xA0;min. Cell lysates were centrifuged (18,000&#xA0;<italic>g</italic> for 10&#xA0;min at 4&#xB0;C) and the supernatants (5&#xA0;&#x3BC;l/well) were transferred to 96-well plates. A selective caspase-3 inhibitor (<italic>N</italic>-acetyl-Asp-Glu-Val-Asp-CHO; 10&#xA0;&#x3BC;l/well at 200&#xA0;&#x3BC;M) was added to supernatants to control for the nonspecific hydrolysis of the substrate. Purified caspase-3 human recombinant protein, provided with the assay, was used (5&#xA0;&#x3BC;l/well at 5&#xA0;&#x3BC;g/ml) as a positive control for caspase-3 activity. Cell lysates were incubated in an assay buffer [40&#xA0;mM HEPES, pH 7.4, 1% CHAPS, 10&#xA0;mM DTT, 4&#xA0;mM ethylenediaminetetraacetic acid (EDTA)], containing <italic>N</italic>-acetyl-Asp-Glu-Val-Asp <italic>p</italic>-nitroaniline (10&#xA0;&#x3BC;l/well at 2&#xA0;mM) overnight at 37&#xB0;C and the formation of <italic>p</italic>-nitroaniline was measured at 405&#xA0;nm, using a microtiter plate reader. The activity of caspase-3 was calculated from the absorbance values using a calibration curve, and it is expressed as &#x3BC;g of substrate cleaved/min per ml. As the number of cells in 1&#xA0;ml of cell lysate is adjusted to 1&#x2009;&#xD7;&#x2009;10<sup>8</sup> cells, this caspase-3 activity is generated by 1&#x2009;&#xD7;&#x2009;10<sup>8</sup> cells.</p>
      </sec>
      <sec id="Sec6">
        <title>Measurement of &#x3B1;-synuclein protein concentration by ELISA</title>
        <p>The concentration of &#x3B1;-synuclein protein in SH-SY5Y neuroblastoma cells was determined by an ELISA (BioSource, San Diego, CA, USA). Cells were exposed to various treatments as described above and subsequently lysed using a cell extraction buffer (10&#xA0;mM Tris, pH 7.4, 100&#xA0;mM NaCl, 1&#xA0;mM EDTA, 1&#xA0;mM NaF, 20&#xA0;mM Na<sub>4</sub>P<sub>2</sub>O<sub>7</sub>, 2&#xA0;mM Na<sub>3</sub>VO<sub>4</sub>, 1% Triton X-100, 10% glycerol, 0.1% sodium dodecyl sulfate, 0.5% deoxycholate; BioSource, San Diego, CA, USA), containing protease inhibitors [1&#xA0;mM phenylmethanesulfonyl fluoride, 2&#xA0;mM 4-(2-aminoethyl) benzenesulfonyl fluoride, 130&#xA0;&#x3BC;M bestatin, 14&#xA0;&#x3BC;M E-64, 1&#xA0;&#x3BC;M leupeptin, 0.3&#xA0;&#x3BC;M aprotinin; Sigma]. Cells were incubated on ice in cell extraction buffer for 30&#xA0;min and centrifuged (14,000&#xA0;<italic>g</italic> for 10&#xA0;min at 4&#xB0;C). Aliquots of supernatants (25&#xA0;&#x3BC;l) were removed for the determination of the total protein concentration using the bicinchoninic acid (BCA) protein assay (Pierce, Rockford, IL, USA). We measured &#x3B1;-synuclein protein concentration using an ELISA kit according to the manufacturer&#x2019;s instructions. Briefly, cell lysates (diluted 1:10) were added to &#x3B1;-synuclein antibody-coated wells in duplicate, allowed to bind and then were treated with the anti-&#x3B1;-synuclein antibody. This was followed by the addition of an anti-rabbit IgG-horse radish peroxidase-linked antibody, and by the addition of a stabilized chromogen (tetramethylbenzidine). The reaction was terminated by adding 1&#xA0;M HCl (stop solution) provided with the kit, and the absorbance of each well was read at 450&#xA0;nm. Standard curves were prepared using purified recombinant &#x3B1;-synuclein protein (100&#xA0;ng/ml) provided with the kit. The concentration of the &#x3B1;-synuclein protein in each sample was determined from a nonlinear regression, and it is expressed as a ratio of &#x3B1;-synuclein protein (in ng/ml) to total protein concentration (in ng/ml).</p>
      </sec>
      <sec id="Sec7">
        <title>Statistical analysis</title>
        <p>Data obtained in experiments testing the concentration dependence of the protective effect of guanosine on MPP<sup>+</sup>-induced DNA fragmentation (Fig.&#xA0;<xref rid="Fig3" ref-type="fig">3</xref>) and the effect of PTX, and inhibitors of the PI-3-K, and the MAPK pathways on DNA fragmentation (Fig.&#xA0;<xref rid="Fig6" ref-type="fig">6</xref> and Table&#xA0;<xref rid="Tab1" ref-type="table">1</xref>) were analyzed by a one-way analysis of variance (ANOVA) followed by a Student-Newman-Keul post-hoc test. Two-way ANOVA, followed by a Bonferroni post-hoc test, was used to analyze the data obtained from experiments evaluating the effects of guanosine, administered at different time points on MPP<sup>+</sup>-induced DNA fragmentation (Fig.&#xA0;<xref rid="Fig4" ref-type="fig">4</xref>) and on MPP<sup>+</sup>-induced caspase-3 activation (Fig.&#xA0;<xref rid="Fig5" ref-type="fig">5</xref>). A <italic>p</italic> value of 0.05 or less was considered statistically significant. Results represent the mean &#xB1; SEM of a minimum of three independent experiments.
<table-wrap id="Tab1"><label>Table&#xA0;1</label><caption><p>Effect of selected inhibitors of cell survival pathways on the anti-apoptotic effect of guanosine in SH-SY5Y cells</p></caption><table frame="hsides" rules="groups"><thead><tr><th rowspan="2">Treatment</th><th colspan="3">DNA fragmentation (% of positive control)</th></tr><tr><th>No inhibitor</th><th>LY294002 10&#xA0;&#x3BC;M</th><th>PD98059 10&#xA0;&#x3BC;M</th></tr></thead><tbody><tr><td>Control</td><td>10.1&#x2009;&#xB1;&#x2009;1.3</td><td>16.3&#x2009;&#xB1;&#x2009;3.1</td><td>24.0&#x2009;&#xB1;&#x2009;4.7</td></tr><tr><td>MPP<sup>+</sup> (500&#xA0;&#x3BC;M)</td><td>34.5&#x2009;&#xB1;&#x2009;4.3<sup>a</sup></td><td>&#x2013;</td><td>&#x2013;</td></tr><tr><td>Guanosine pre-treatment</td><td>15.9&#x2009;&#xB1;&#x2009;4.8</td><td>38.6&#x2009;&#xB1;&#x2009;10.3<sup>b</sup></td><td>38.3&#x2009;&#xB1;&#x2009;9.1<sup>b</sup></td></tr><tr><td>Guanosine co-treatment</td><td>11.0&#x2009;&#xB1;&#x2009;0.7</td><td>32.9&#x2009;&#xB1;&#x2009;5.7<sup>b</sup></td><td>28.7&#x2009;&#xB1;&#x2009;10.4<sup>n.s.</sup></td></tr><tr><td>Guanosine post-treatment</td><td>12.4&#x2009;&#xB1;&#x2009;1.8</td><td>48.2&#x2009;&#xB1;&#x2009;4.3<sup>c</sup></td><td>28.4&#x2009;&#xB1;&#x2009;4.8<sup>n.s.</sup></td></tr></tbody></table><table-wrap-foot><p>SH-SY5Y cells were exposed to MPP<sup>+</sup> (500&#xA0;&#x3BC;M) for 48&#xA0;h to induce DNA fragmentation. Some cells were treated with guanosine (100&#xA0;&#x3BC;M) either for 1&#xA0;h prior to MPP<sup>+</sup> (<italic>pre-treatment</italic>), or at the same time as MPP<sup>+</sup> (<italic>co-treatment</italic>) or 24&#xA0;h after MPP<sup>+</sup> (<italic>post-treatment</italic>, see Fig.&#xA0;<xref rid="Fig1" ref-type="fig">1</xref>). Some cultures were exposed to LY294002 (inhibitor of PI-3-K) or to PD98059 (inhibitor of MAP kinase kinase, MEK) for 20&#xA0;min prior to the addition of guanosine. DNA fragmentation was determined at 48&#xA0;h (<italic>n</italic>&#x2009;=&#x2009;3) and is expressed as a percentage of the positive control. LY294002 abolished the protective effect of guanosine in cells <italic>pre-treated</italic>, <italic>co-treated</italic> or <italic>post-treated</italic> with this nucleoside. PD98059 also abolished the protective effect of guanosine in cells <italic>pre-treated</italic> with this nucleoside, but had no significant effect in cells <italic>co-treated or post-treated</italic> with guanosine</p><p><sup>a</sup><italic>p</italic>&#x2009;&lt;&#x2009;0.001 compared to control</p><p><sup>b</sup><italic>p</italic>&#x2009;&lt;&#x2009;0.01 compared to same treatment without inhibitor</p><p><sup>c</sup><italic>p</italic>&#x2009;&lt;&#x2009;0.05 compared to same treatment without inhibitor</p><p><italic>n.s.</italic>&#x2009;not significant</p></table-wrap-foot></table-wrap></p>
      </sec>
    </sec>
    <sec id="Sec8" sec-type="results">
      <title>Results</title>
      <sec id="Sec9">
        <title>MPP<sup>+</sup> induces DNA fragmentation in SH-SY5Y neuroblastoma cells</title>
        <p>SH-SY5Y neuroblastoma cells were exposed to different concentrations of MPP<sup>+</sup> (10&#x2013;500&#xA0;&#x3BC;M) for various times (0&#x2013;72&#xA0;h) to optimize the experimental conditions and to confirm that MPP<sup>+</sup>-induced DNA fragmentation was concentration and time dependent (Fig.&#xA0;<xref rid="Fig2" ref-type="fig">2</xref>). DNA fragmentation in untreated control cells was around 10% and remained unchanged for up to 72&#xA0;h (Fig.&#xA0;<xref rid="Fig2" ref-type="fig">2</xref>). Treatment of cells with 500&#xA0;&#x3BC;M MPP<sup>+</sup> increased DNA fragmentation significantly after 48&#xA0;h (<italic>p</italic>&#x2009;&lt;&#x2009;0.01) and 72&#xA0;h (<italic>p</italic>&#x2009;&lt;&#x2009;0.001; Fig.&#xA0;<xref rid="Fig2" ref-type="fig">2</xref>) compared to untreated controls. Since exposure of cells to 500&#xA0;&#x3BC;M MPP<sup>+</sup> for 48&#xA0;h induced robust DNA fragmentation, these conditions were used in the following studies.
<fig id="Fig2"><label>Fig.&#xA0;2</label><caption><p>MPP<sup>+</sup> induces DNA fragmentation in SH-SY5Y cells. MPP<sup>+</sup> (10, 100 or 500&#xA0;&#x3BC;M) was added to SH-SY5Y cells and DNA fragmentation determined after 24, 48 or 72&#xA0;h by oligonucleosomal ELISA as described in the &#x201C;<xref rid="Sec2" ref-type="sec">Materials and methods</xref>&#x201D; section. Data are presented as the percentage of DNA fragmentation relative to a positive control (<italic>n</italic>&#x2009;&gt;&#x2009;3). MPP<sup>+</sup> (500&#xA0;&#x3BC;M) increased DNA fragmentation significantly at 48 h (*<italic>p</italic>&#x2009;&lt;&#x2009;0.01) and at 72&#xA0;h (**<italic>p</italic>&#x2009;&lt;&#x2009;0.001) compared to that of untreated cells at zero time</p></caption><graphic position="anchor" xlink:href="11302_2007_9073_Fig2_HTML" id="MO2"/></fig></p>
      </sec>
      <sec id="Sec10">
        <title>Pre-treatment of SH-SY5Y neuroblastoma cells with guanosine attenuates MPP<sup>+</sup>-induced DNA fragmentation</title>
        <p>SH-SY5Y cells were exposed to various concentrations of guanosine (1&#x2013;300&#xA0;&#x3BC;M) for 1&#xA0;h, followed by the addition of 500&#xA0;&#x3BC;M MPP<sup>+</sup> for a further 48&#xA0;h, and DNA fragmentation was determined at 49&#xA0;h by oligonucleosomal ELISA. As we observed in the previous experiment the addition of MPP<sup>+</sup> (500&#xA0;&#x3BC;M) led to significantly increased DNA fragmentation compared to controls (<italic>p</italic>&#x2009;&lt;&#x2009;0.001; Fig.&#xA0;<xref rid="Fig3" ref-type="fig">3</xref>). Pre-treatment of cells for 1&#xA0;h with various concentrations of guanosine (10&#x2013;300&#xA0;&#x3BC;M) significantly reduced MPP<sup>+</sup>-induced DNA fragmentation (<italic>p</italic>&#x2009;&lt;&#x2009;0.05) for all four concentrations of guanosine compared to cells treated with MPP<sup>+</sup> alone (Fig.&#xA0;<xref rid="Fig3" ref-type="fig">3</xref>). Based on these results, we used 100&#xA0;&#x3BC;M guanosine in all subsequent experiments.
<fig id="Fig3"><label>Fig.&#xA0;3</label><caption><p>Pre-treatment of SH-SY5Y cells with guanosine decreases MPP<sup>+</sup>-induced DNA fragmentation. SH-SY5Y cells were exposed to MPP<sup>+</sup> (500&#xA0;&#x3BC;M) for 48&#xA0;h to induce DNA fragmentation. Some cells were pre-treated with guanosine (1&#x2013;300&#xA0;&#x3BC;M) for 1&#xA0;h prior to MPP<sup>+</sup>. Guanosine and MPP<sup>+</sup> remained in the cultures for the duration of the experiment. DNA fragmentation was determined after 48&#xA0;h by oligonucleosomal ELISA as described in the &#x201C;<xref rid="Sec2" ref-type="sec">Materials and methods</xref>&#x201D; section and is expressed as the percentage of the positive control (<italic>n</italic>&#x2009;&gt;&#x2009;3). MPP<sup>+</sup> increased DNA fragmentation significantly at 48 h compared to that of untreated controls (*<italic>p</italic>&#x2009;&lt;&#x2009;0.001). Pre-treatment with guanosine (10&#x2013;300&#xA0;&#x3BC;M) reduced significantly the MPP<sup>+</sup>-induced DNA fragmentation compared to that in cells treated with MPP<sup>+</sup> for the same time (#<italic>p</italic>&#x2009;&lt;&#x2009;0.05, at all four concentrations)</p></caption><graphic position="anchor" xlink:href="11302_2007_9073_Fig3_HTML" id="MO3"/></fig></p>
      </sec>
      <sec id="Sec11">
        <title>Post-treatment with guanosine protects SH-SY5Y neuroblastoma cells against MPP<sup>+</sup>-induced DNA fragmentation</title>
        <p>We next examined whether guanosine exerted any effect on MPP<sup>+</sup>-induced DNA fragmentation when it was added to neuroblastoma cells after apoptosis was already in progress. Cells were pre-treated with 100&#xA0;&#x3BC;M guanosine prior to MPP<sup>+</sup> or co-treated with guanosine plus MPP<sup>+</sup> or, as described in Fig.&#xA0;<xref rid="Fig1" ref-type="fig">1</xref>, guanosine was added as <italic>post-treatment</italic>. DNA fragmentation was determined in cells exposed to various treatments after 24, 48 and 72&#xA0;h of MPP<sup>+</sup> administration (Fig.&#xA0;<xref rid="Fig4" ref-type="fig">4</xref>). The addition of MPP<sup>+</sup> led to a significant increase in DNA fragmentation compared to controls at 48&#xA0;h (<italic>p</italic>&#x2009;&lt;&#x2009;0.01) and 72&#xA0;h (<italic>p</italic>&#x2009;&lt;&#x2009;0.001) (Fig.&#xA0;<xref rid="Fig4" ref-type="fig">4</xref>). Guanosine alone had no significant effect on DNA fragmentation (Fig.&#xA0;<xref rid="Fig4" ref-type="fig">4</xref>). <italic>Pre-treatment</italic> of cells with guanosine significantly reduced DNA fragmentation after 48&#xA0;and 72&#xA0;h compared to MPP<sup>+</sup> treatment alone, at the respective time points (<italic>p</italic>&#x2009;&lt;&#x2009;0.05, at both time points; Fig.&#xA0;<xref rid="Fig4" ref-type="fig">4</xref>). Similarly, <italic>co-treatment</italic> of cells with guanosine plus MPP<sup>+</sup> significantly reduced DNA fragmentation after 48&#xA0;and 72&#xA0;h compared to cells treated with MPP<sup>+</sup> alone at these times (<italic>p</italic>&#x2009;&lt;&#x2009;0.05, at both time points; Fig.&#xA0;<xref rid="Fig4" ref-type="fig">4</xref>). Addition of guanosine 24&#xA0;h after MPP<sup>+</sup> (<italic>post-treatment at 24&#xA0;h</italic>) or 48&#xA0;h after MPP<sup>+</sup> (<italic>post-treatment at 48&#xA0;h</italic>) reduced DNA fragmentation significantly compared to cells treated with MPP<sup>+</sup> alone for 48&#xA0;or 72&#xA0;h, respectively (<italic>p</italic>&#x2009;&lt;&#x2009;0.05, for both treatments; Fig.&#xA0;<xref rid="Fig4" ref-type="fig">4</xref>). These results demonstrate that <italic>pre-treatment</italic> or <italic>co-treatment</italic> of cells with guanosine and MPP<sup>+</sup> attenuates MPP<sup>+</sup>-induced DNA fragmentation, and guanosine added 24 or 48&#xA0;h after the start of the DNA fragmentation (<italic>post-treatment</italic>) can actually reverse this process.
<fig id="Fig4"><label>Fig.&#xA0;4</label><caption><p>Guanosine antagonizes and reverses MPP<sup>+</sup>-induced DNA fragmentation in SH-SY5Y cells. SH-SY5Y cells were exposed to MPP<sup>+</sup> (500&#xA0;&#x3BC;M) for 48&#xA0;h to induce DNA fragmentation. Some cells were treated with guanosine (100&#xA0;&#x3BC;M) either for 1&#xA0;h prior to MPP<sup>+</sup> (<italic>pre-treatment</italic>), or at the same time as MPP<sup>+</sup> (<italic>co-treatment</italic>) or 24&#xA0;or 48&#xA0;h after MPP<sup>+</sup> (<italic>post-treatment</italic>, see Fig. <xref rid="Fig1" ref-type="fig">1</xref>). DNA fragmentation was determined after 24, 48 or 72&#xA0;h of MPP<sup>+</sup> addition by oligonucleosomal ELISA as described in the &#x201C;<xref rid="Sec2" ref-type="sec">Materials and methods</xref>&#x201D; section and it is expressed as a percentage of the positive control (<italic>n</italic>&#x2009;&gt;&#x2009;3). MPP<sup>+</sup> induced a significant increase in DNA fragmentation at 48&#xA0;(*<italic>p</italic>&#x2009;&lt;&#x2009;0.01) and at 72&#xA0;h (**<italic>p</italic>&#x2009;&lt;&#x2009;0.001) compared to that of untreated control cells at the same time. <italic>Pre-treatment</italic> or <italic>co-treatment</italic> of cells with guanosine significantly reduced MPP<sup>+</sup>-induced DNA fragmentation at 48 and 72&#xA0;h compared to that in cells treated with MPP<sup>+</sup> alone at the same time (#<italic>p</italic>&#x2009;&lt;&#x2009;0.05 at both time points, for both treatments). <italic>Post-treatment</italic> with guanosine at 24&#xA0;or 48&#xA0;h also reduced MPP<sup>+</sup>-induced DNA fragmentation at 48&#xA0;and 72&#xA0;h compared to that in cells treated with MPP<sup>+</sup> alone at the same time (#<italic>p</italic>&#x2009;&lt;&#x2009;0.05, at both time points)</p></caption><graphic position="anchor" xlink:href="11302_2007_9073_Fig4_HTML" id="MO4"/></fig></p>
      </sec>
      <sec id="Sec12">
        <title>Guanosine inhibits MPP<sup>+</sup>-induced caspase-3 activity</title>
        <p>Exposure of SH-SY5Y cells to MPP<sup>+</sup> leads to apoptosis via caspase-3 activation [<xref ref-type="bibr" rid="CR23">23</xref>, <xref ref-type="bibr" rid="CR26">26</xref>]. We therefore examined if under our experimental conditions treatment of neuroblastoma cells with MPP<sup>+</sup> activated caspase-3 and whether the addition of guanosine to MPP<sup>+</sup>-treated cells at various times (<italic>pre-treatment, co-treatment or post-treatment</italic>) had any effect on the activity of this enzyme. In untreated control cells caspase-3 activity was low and remained unchanged for up to 72&#xA0;h (Fig.&#xA0;<xref rid="Fig5" ref-type="fig">5</xref>). Addition of guanosine to cells had no significant effect on caspase-3 activity (Fig.&#xA0;<xref rid="Fig5" ref-type="fig">5</xref>). In MPP<sup>+</sup>-treated cells caspase-3 activity increased significantly from 24 to 72&#xA0;h (<italic>p</italic>&#x2009;&lt;&#x2009;0.001, at all time points; Fig.&#xA0;<xref rid="Fig5" ref-type="fig">5</xref>). <italic>Pre-treatment</italic> of cells with guanosine prior to MPP<sup>+</sup> addition significantly reduced caspase-3 activity after 48 or 72&#xA0;h compared to that in cells treated with MPP<sup>+</sup> alone for the same time (<italic>p</italic>&#x2009;&lt;&#x2009;0.01, at both time points; Fig.&#xA0;<xref rid="Fig5" ref-type="fig">5</xref>). Similar results were also obtained when cells were <italic>co-treated</italic> with guanosine and MPP<sup>+</sup> for 48 and 72&#xA0;h (<italic>p</italic>&#x2009;&lt;&#x2009;0.01, at both time points; Fig.&#xA0;<xref rid="Fig5" ref-type="fig">5</xref>). <italic>Post-treatment with guanosine at 24&#xA0;h</italic> (see Fig.&#xA0;<xref rid="Fig1" ref-type="fig">1</xref>) also reduced caspase-3 activity significantly at 48&#xA0;h compared to that in cells treated with MPP<sup>+</sup> alone at this time point (<italic>p</italic>&#x2009;&lt;&#x2009;0.01; Fig.&#xA0;<xref rid="Fig5" ref-type="fig">5</xref>). When guanosine was added to cells 48&#xA0;h after the addition of MPP<sup>+</sup> (<italic>post-treatment at 48&#xA0;h</italic>), caspase-3 activity determined after 72&#xA0;h was unaffected compared to MPP<sup>+</sup> treatment alone at this time point (Fig.&#xA0;<xref rid="Fig5" ref-type="fig">5</xref>). These results thus demonstrate that <italic>pre-treatment, co-treatment</italic> or <italic>post-treatment at 24&#xA0;h</italic> of neuroblastoma cells with guanosine prevents MPP<sup>+</sup>-induced activation of caspase-3. Administration of guanosine to cells 48&#xA0;h after MPP<sup>+</sup> however has no effect on caspase-3 activity.
<fig id="Fig5"><label>Fig.&#xA0;5</label><caption><p>Guanosine inhibits MPP<sup>+</sup>-induced caspase-3 activation in SH-SY5Y cells. SH-SY5Y cells were exposed to MPP<sup>+</sup> (500&#xA0;&#x3BC;M) for 48&#xA0;h to induce to induce caspase-3 activation. Some cells were treated with guanosine (100&#xA0;&#x3BC;M) either for 1&#xA0;h prior to MPP<sup>+</sup> (<italic>pre-treatment</italic>), or at the same time as MPP<sup>+</sup> (<italic>co-treatment</italic>) or 24&#xA0;or 48&#xA0;h after MPP<sup>+</sup> (<italic>post-treatment</italic>, see Fig. <xref rid="Fig1" ref-type="fig">1</xref>). Caspase-3 activity was determined as described in the &#x201C;<xref rid="Sec2" ref-type="sec">Materials and methods</xref>&#x201D; section and is expressed as the amount of <italic>N</italic>-acetyl-Asp-Glu-Val-Asp <italic>p</italic>-nitroaniline cleaved by 1&#x2009;&#xD7;&#x2009;10<sup>8</sup> cells, in &#x3BC;g/min per ml (<italic>n</italic>&#x2009;&gt;&#x2009;3). MPP<sup>+</sup> significantly increased caspase-3 activity from 24&#xA0;to 72&#xA0;h (*<italic>p</italic>&#x2009;&lt;&#x2009;0.001, at all three time points) compared to that of control cells at the same time. <italic>Pre-treatment</italic> or <italic>co-treatment</italic> of cells with guanosine significantly reduced MPP<sup>+</sup>-induced caspase-3 activity, at 48 and 72&#xA0;h, compared to that in cells treated with MPP<sup>+</sup> alone at the same time (#<italic>p</italic>&#x2009;&lt;&#x2009;0.01, at both time points, for both treatments). <italic>Post-treatment</italic> with guanosine at 24 h reduced MPP<sup>+</sup>-induced caspase-3 activity at 48&#xA0;h compared to that in cells treated with MPP<sup>+</sup> alone at the same time (#<italic>p</italic>&#x2009;&lt;&#x2009;0.01). Guanosine added to cultures 48&#xA0;h after MPP<sup>+</sup> had no effect on caspase-3 activity</p></caption><graphic position="anchor" xlink:href="11302_2007_9073_Fig5_HTML" id="MO5"/></fig></p>
      </sec>
      <sec id="Sec13">
        <title>Guanosine has no effect on &#x3B1;-synuclein protein expression in MPP<sup>+</sup>-treated neuroblastoma cells</title>
        <p>Several authors reported that addition of MPP<sup>+</sup> to SH-SY5Y cells increased &#x3B1;-synuclein protein expression [<xref ref-type="bibr" rid="CR27">27</xref>, <xref ref-type="bibr" rid="CR29">29</xref>]. We therefore determined &#x3B1;-synuclein protein concentration in neuroblastoma cells under our experimental conditions (500&#xA0;&#x3BC;M MPP<sup>+</sup> for 48&#xA0;h) and evaluated the effects of guanosine on the expression of this protein in MPP<sup>+</sup>-treated cells. The ratio of &#x3B1;-synuclein protein/total protein in untreated control cells after 48&#xA0;h was very low and exposure of neuroblastoma cells to MPP<sup>+</sup> for 48&#xA0;h had no significant effect on the expression of this protein (data not shown). Treatment of cells with guanosine prior to the addition of MPP<sup>+</sup>, or at the same time as MPP<sup>+</sup> or 24&#xA0;h after MPP<sup>+</sup> had no significant effect on of &#x3B1;-synuclein protein expression (data not shown). These results indicate that under the present experimental conditions neither MPP<sup>+</sup> nor a combination of guanosine plus MPP<sup>+</sup> has any effect on &#x3B1;-synuclein protein expression.</p>
      </sec>
      <sec id="Sec14">
        <title>Pertussis toxin abolishes the anti-apoptotic effect of guanosine</title>
        <p>We reported recently that specific binding sites exist for guanosine in rat brain membranes [<xref ref-type="bibr" rid="CR35">35</xref>], in cultured rat astrocytes [<xref ref-type="bibr" rid="CR36">36</xref>] and in SH-SY5Y neuroblastoma cells (Traversa and Caciagli, 2005, personal communications). We have further shown that guanosine binding in these cells is sensitive to treatment with PTX [<xref ref-type="bibr" rid="CR37">37</xref>, <xref ref-type="bibr" rid="CR40">40</xref>], indicating that the putative guanosine receptor is coupled to Gi protein. We therefore tested whether the anti-apoptotic effect of guanosine in the MPP<sup>+</sup>-treated cells is mediated via this putative guanosine receptor. Cells were exposed to PTX (200&#xA0;ng/ml for 16&#xA0;h) prior to the various treatments with guanosine and MPP<sup>+</sup> (<italic>pre-treatment, co-treatment or post-treatment at 24&#xA0;h</italic>) and DNA fragmentation was determined at 48&#xA0;h. As in previous experiments, MPP<sup>+</sup> induced a significant increase in DNA fragmentation and the addition of guanosine alone had no significant effect on this process (Fig.&#xA0;<xref rid="Fig6" ref-type="fig">6</xref>). Exposure of neuroblastoma cells to PTX alone increased DNA fragmentation slightly under basal conditions, but this was not statistically significant. <italic>Pre-treatment, co-treatment or post-treatment at 24&#xA0;h</italic> of cells with guanosine and MPP<sup>+</sup> significantly reduced DNA fragmentation compared to cells treated with MPP<sup>+</sup> only (<italic>p</italic>&#x2009;&lt;&#x2009;0.01, for all three treatments; Fig.&#xA0;<xref rid="Fig6" ref-type="fig">6</xref>). Addition of PTX to neuroblastoma cells prior to any of the three guanosine plus MPP<sup>+</sup> treatments reversed the anti-apoptotic effect of guanosine (Fig.&#xA0;<xref rid="Fig6" ref-type="fig">6</xref>). These results demonstrate that regardless of the time of its addition to MPP<sup>+</sup>-treated cells, the protective effect of guanosine is abolished by PTX. These findings are consistent with the interpretation that these effects are mediated by a Gi protein-coupled receptor, most likely the putative guanosine receptor.
<fig id="Fig6"><label>Fig.&#xA0;6</label><caption><p>Pertussis toxin abolishes the anti-apoptotic effect of guanosine in SH-SY5Y cells. SH-SY5Y cells were exposed to MPP<sup>+</sup> (500&#xA0;&#x3BC;M) for 48&#xA0;h to induce DNA fragmentation. Some cells were treated with guanosine (100&#xA0;&#x3BC;M) either for 1&#xA0;h prior to MPP<sup>+</sup> (<italic>pre-treatment</italic>), or at the same time as MPP<sup>+</sup> (<italic>co-treatment</italic>) or 24&#xA0;h after MPP<sup>+</sup> (<italic>post-treatment</italic>, see Fig. <xref rid="Fig1" ref-type="fig">1</xref>). Pertussis toxin (PTX, 200&#xA0;ng/ml for 16&#xA0;h) was added to some cultures prior to <italic>pre-treatment</italic> or <italic>co-treatment</italic> or <italic>post-treatment</italic> with guanosine at 24&#xA0;h. DNA fragmentation was determined at 48&#xA0;h and is expressed as a percentage of the positive control (<italic>n</italic>&#x2009;&gt;&#x2009;3). MPP<sup>+</sup> increased DNA fragmentation significantly at 48&#xA0;h (*<italic>p</italic>&#x2009;&lt;&#x2009;0.001) compared to that of untreated control cells at the same time. <italic>Pre-treatment, or co-treatment</italic> or <italic>post-treatment</italic> of cells with guanosine at 24&#xA0;h reduced significantly MPP<sup>+</sup>-induced DNA fragmentation compared to that in cells treated with MPP<sup>+</sup> alone at the same time (<sup>&#xA7;</sup><italic>p</italic>&#x2009;&lt;&#x2009;0.01). PTX reversed the protective effect of guanosine. DNA fragmentation in cells exposed to PTX plus <italic>pre-treatment</italic>, or <italic>co-treatment</italic> or <italic>post-treatment</italic> with guanosine was significantly higher compared to that of cells without PTX (<sup>#</sup><italic>p</italic>&#x2009;&lt;&#x2009;0.05, for all three treatments). These values were comparable to that obtained in cells treated with MPP<sup>+</sup> alone</p></caption><graphic position="anchor" xlink:href="11302_2007_9073_Fig6_HTML" id="MO6"/></fig></p>
      </sec>
      <sec id="Sec15">
        <title>Guanosine protects against MPP<sup>+</sup>-induced apoptosis by activating the cell survival pathways</title>
        <p>We have shown earlier that guanosine activates the PI-3-K/Akt/PKB and MAPK pathways in neuroblastoma cells [<xref ref-type="bibr" rid="CR34">34</xref>]. We therefore evaluated if the protective effects of guanosine against MPP<sup>+</sup>-induced DNA fragmentation were also mediated via these signaling pathways. Cells were exposed to either LY294002, or to PD98059, selective inhibitors of PI-3-K or MEK, respectively, for 20&#xA0;min prior to various treatments with guanosine and MPP<sup>+</sup> (<italic>pre-treatment, co-treatment or post-treatment at 24&#xA0;h</italic>). Exposure of neuroblastoma cells to LY294002 alone had no significant effect on DNA fragmentation under basal conditions. Although in cells exposed to PD98059 alone DNA fragmentation increased slightly, this was not statistically significant (Table&#xA0;<xref rid="Tab1" ref-type="table">1</xref>). As in previous experiments, the addition of MPP<sup>+</sup> induced significant DNA fragmentation and treatment of cells with guanosine under various conditions significantly reduced DNA fragmentation compared to cells treated with guanosine (Table&#xA0;<xref rid="Tab1" ref-type="table">1</xref>).</p>
        <p>Exposure of cells to LY294002 prior to <italic>pre-treatment, or co-treatment or post-treatment at 24&#xA0;h</italic> with guanosine and MPP<sup>+</sup> reversed the protective effect of guanosine. DNA fragmentation in cells exposed to LY294002 plus guanosine plus MPP<sup>+</sup> was significantly reduced compared to cells treated with guanosine plus MPP<sup>+</sup> without the inhibitor (<italic>p</italic>&#x2009;&lt;&#x2009;0.05, for <italic>pre-treatment</italic> and <italic>co-treatment</italic>; <italic>p</italic>&#x2009;&lt;&#x2009;0.01, for <italic>post-treatment at 24&#xA0;h</italic>; Table&#xA0;<xref rid="Tab1" ref-type="table">1</xref>). Addition of PD98059 to cells before <italic>pre-treatment</italic> with guanosine and MPP<sup>+</sup> also abolished the protective effect of guanosine (<italic>p</italic>&#x2009;&lt;&#x2009;0.05; Table&#xA0;<xref rid="Tab1" ref-type="table">1</xref>). But this inhibitor had no significant effect on MPP<sup>+</sup>-induced DNA fragmentation in cells <italic>co-treated</italic> or <italic>post-treated at 24</italic> with guanosine and MPP<sup>+</sup> (Table&#xA0;<xref rid="Tab1" ref-type="table">1</xref>). These results demonstrate that the protective effects of guanosine are abolished by LY294002 in MPP<sup>+</sup>-treated cells regardless of the time of its administration and are consistent with a role of the PI-3-K/Akt/PKB cell survival pathway in guanosine-mediated reduction of DNA fragmentation. In contrast, the effect of PD98059 is limited to pre-treatment of cells with guanosine prior to MPP<sup>+</sup>, thus indicating that the MAPK pathway contributes to the protective effects of guanosine only when it is added before MPP<sup>+</sup>.</p>
      </sec>
    </sec>
    <sec id="Sec16" sec-type="discussion">
      <title>Discussion</title>
      <p>We have shown earlier that pre-treatment with guanosine protects different cell types against apoptosis [<xref ref-type="bibr" rid="CR33">33</xref>, <xref ref-type="bibr" rid="CR34">34</xref>]. Here, we report that guanosine not only protects human SH-SY5Y neuroblastoma cells against MPP<sup>+</sup>-induced apoptosis, but more importantly, it can reverse MPP<sup>+</sup>-induced cytotoxicity after the pro-apoptotic pathways have already been activated. Thus, these findings are novel and demonstrate for the first time that guanosine can in fact &#x2018;rescue&#x2019; neuroblastoma cells from apoptosis when it is added to cells under experimental conditions that are &#x2018;clinically relevant&#x2019; to the treatment of PD.</p>
      <p>Undifferentiated dopaminergic human SH-SY5Y neuroblastoma cells have been used widely to study the molecular pathways that mediate MPP<sup>+</sup>-induced apoptosis [<xref ref-type="bibr" rid="CR23">23</xref>&#x2013;<xref ref-type="bibr" rid="CR29">29</xref>]. MPTP, after conversion to MPP<sup>+</sup>, activates the same intracellular pathways in vivo and in vitro as in idiopathic PD [<xref ref-type="bibr" rid="CR2">2</xref>]. Thus, MPP<sup>+</sup> is taken up by dopaminergic neurons, where it inhibits complex I of the mitochondrial electron transport chain. This leads to enhanced production of reactive oxygen species (ROS) and decreased synthesis of ATP [<xref ref-type="bibr" rid="CR2">2</xref>]. Prolonged exposure to MPP<sup>+</sup> results in the up-regulation of the pro-apoptotic protein Bax, and following its translocation to the mitochondria it promotes the release of mitochondrial cytochrome <italic>c</italic>. This may be initiated by the DNA damage caused by MPP<sup>+</sup>. Cytochrome <italic>c</italic>, together with pro-caspase-9, is incorporated into the complex, the apoptosome, which activates caspase-9, and this enzyme in turn activates caspase-3 [<xref ref-type="bibr" rid="CR2">2</xref>, <xref ref-type="bibr" rid="CR41">41</xref>]. At the same time, the anti-apoptotic protein, Bcl-2, is down-regulated [<xref ref-type="bibr" rid="CR42">42</xref>]. Taken together these data demonstrate that exposure of dopaminergic cells to MPP<sup>+</sup> leads to cytotoxicity and cell death by apoptosis [<xref ref-type="bibr" rid="CR2">2</xref>, <xref ref-type="bibr" rid="CR17">17</xref>]. Our findings are consistent with previous reports that MPP<sup>+</sup> induces DNA fragmentation and activation of caspase-3 in SH-SY5Y cells [<xref ref-type="bibr" rid="CR23">23</xref>, <xref ref-type="bibr" rid="CR25">25</xref>]. Interestingly, we detected no significant change in &#x3B1;-synuclein protein expression in MPP<sup>+</sup>-treated cells (data not shown). This may be the result of the relatively low MPP<sup>+</sup> concentration (500&#xA0;&#x3BC;M) and short duration of our experiments (48&#xA0;h). Others reported that high concentrations of MPP<sup>+</sup> (5&#xA0;mM for 12&#xA0;h [<xref ref-type="bibr" rid="CR29">29</xref>]) or prolonged exposure of neuroblastoma cells to lower concentrations of MPP<sup>+</sup> (5&#xA0;&#x3BC;M for 4&#xA0;days [<xref ref-type="bibr" rid="CR28">28</xref>] or 1&#xA0;mM for 3&#xA0;days [<xref ref-type="bibr" rid="CR27">27</xref>]) actually increased &#x3B1;-synuclein protein concentration. Mutations of this protein have been associated with a familial form of PD [<xref ref-type="bibr" rid="CR43">43</xref>] and the wild-type protein is a major constituent of Lewy bodies [<xref ref-type="bibr" rid="CR44">44</xref>]. In MPTP-treated mice &#x3B1;-synuclein expression is up-regulated [<xref ref-type="bibr" rid="CR45">45</xref>], and in SH-SY5Y cells accumulation of this protein contributes to dopamine-dependent apoptosis [<xref ref-type="bibr" rid="CR30">30</xref>]. Under our experimental conditions that were optimized to detect DNA fragmentation, we observed no change in &#x3B1;-synuclein protein expression.</p>
      <p>The molecular mechanisms by which guanosine exerts its protective effects are complex. Results from the present study show that the effects of both <italic>pre-treatment</italic> and <italic>co-treatment</italic> with guanosine are pertussis toxin sensitive, and these may depend on the putative plasma membrane localized guanosine receptor [<xref ref-type="bibr" rid="CR35">35</xref>&#x2013;<xref ref-type="bibr" rid="CR37">37</xref>] that is coupled to Gi proteins. There may be other possible explanations, which account for the effects of pertussis toxin on MPP<sup>+</sup>-induced DNA fragmentation. Since pertussis toxin enters cells and ADP-ribosylates the &#x3B1;-subunit of Gi proteins [<xref ref-type="bibr" rid="CR46">46</xref>, <xref ref-type="bibr" rid="CR47">47</xref>], it may also attenuate signaling by other Gi protein-coupled receptors, resulting in the elevation of intracellular cAMP [<xref ref-type="bibr" rid="CR48">48</xref>, <xref ref-type="bibr" rid="CR49">49</xref>] and this in turn may activate cell survival pathways, such as the MAPK [<xref ref-type="bibr" rid="CR56">56</xref>]. Guanosine may also enter neuroblastoma cells via the equilibrative or the concentrative nucleoside transporters [<xref ref-type="bibr" rid="CR50">50</xref>], cause an alteration in intracellular concentrations of guanine nucleotides [<xref ref-type="bibr" rid="CR40">40</xref>] and this in turn may affect G protein activity.</p>
      <p>However, as we have shown before, guanosine binding to its cognate receptor leads to rapid activation of the cell survival pathways, PI-3-K/Akt/PKB and MAPK [<xref ref-type="bibr" rid="CR33">33</xref>, <xref ref-type="bibr" rid="CR34">34</xref>], and these play a critical role in protecting neurons against cell death [<xref ref-type="bibr" rid="CR51">51</xref>&#x2013;<xref ref-type="bibr" rid="CR56">56</xref>]. Although these signaling pathways are most often triggered by growth factor binding to their cognate receptors, G protein-coupled receptors have also been shown to activate them [<xref ref-type="bibr" rid="CR57">57</xref>&#x2013;<xref ref-type="bibr" rid="CR60">60</xref>]. Thus, binding of guanosine to its Gi protein-coupled putative receptor may activate the class IB PI-3-K (PI-3-K&#x3B3;), via the dissociated &#x3B2;,&#x3B3;-subunits of Gi proteins, which promote the synthesis of phosphatidylinositol (3,4,5) trisphosphate at the plasma membrane and recruit the protein kinase, Akt/PKB [<xref ref-type="bibr" rid="CR60">60</xref>, <xref ref-type="bibr" rid="CR61">61</xref>]. Activation of Akt/PKB by phosphorylation at Thr 308 and Ser 473 regulates cell survival and apoptosis by both transcription-dependent and transcription-independent pathways [<xref ref-type="bibr" rid="CR7">7</xref>, <xref ref-type="bibr" rid="CR54">54</xref>, <xref ref-type="bibr" rid="CR61">61</xref>]. Thus, Akt/PKB may suppress apoptosis by phosphorylating and inactivating the pro-apoptotic protein Bad [<xref ref-type="bibr" rid="CR62">62</xref>], inhibiting the release of mitochondrial cytochrome <italic>c</italic> [<xref ref-type="bibr" rid="CR63">63</xref>] and inhibiting the activation of caspase-9 and caspase-3 [<xref ref-type="bibr" rid="CR64">64</xref>]. Expression of cell survival genes may also be triggered by the PI-3-K/Akt/PKB pathway, via activation of the transcription factors CREB and NF-&#x3BA;B, and inhibition of Forkhead transcription factors of the FOXO family [<xref ref-type="bibr" rid="CR54">54</xref>].</p>
      <p>Similarly, activation of the MAPK pathway, specifically the extracellular signal-regulated kinases 1 and 2 (ERK1/2), also prevent apoptosis and promote cell survival by both transcription-dependent and transcription-independent pathways [<xref ref-type="bibr" rid="CR55">55</xref>, <xref ref-type="bibr" rid="CR56">56</xref>, <xref ref-type="bibr" rid="CR65">65</xref>, <xref ref-type="bibr" rid="CR66">66</xref>]. The specific downstream targets of the ERK1/2 pathway include inhibition of caspase-9 by phosphorylation [<xref ref-type="bibr" rid="CR67">67</xref>], suppression of the pro-apoptotic protein Bad by phosphorylation and activation of the transcription factor CREB [<xref ref-type="bibr" rid="CR55">55</xref>]. Guanosine binding to its putative receptor may also stimulate this pathway via the dissociated &#x3B2;,&#x3B3;-subunits of Gi proteins [<xref ref-type="bibr" rid="CR59">59</xref>]. Reports suggest that the PI-3-K/Akt/PKB and MAPK pathways do not function independently, but there is significant cross-talk between them [<xref ref-type="bibr" rid="CR57">57</xref>, <xref ref-type="bibr" rid="CR68">68</xref>]. It has been suggested that whereas the PI-3-K/Akt/PKB pathway is the main signaling pathway for maintaining trophic support by pro-survival factors, ERK1/2 mediates protection against damage-induced cell death [<xref ref-type="bibr" rid="CR56">56</xref>]. Our results are thus consistent with the interpretation that protection of cells from MPP<sup>+</sup>-induced DNA fragmentation by guanosine <italic>pre-treatment</italic> is dependent on the activation of both these pathways. Following <italic>co-treatment</italic> with guanosine and MPP<sup>+</sup>, however, it is the PI-3-K/Akt/PKB pathway, which plays the essential role.</p>
      <p>In the present study, we also examined the effect of guanosine on MPP<sup>+</sup>-induced DNA fragmentation by exposing cells to guanosine <italic>after</italic> caspase-3 activity was elevated and DNA fragmentation was already underway (<italic>post-treatment</italic>). This strategy is novel and is based on a recent proposal by Meissner et al. [<xref ref-type="bibr" rid="CR38">38</xref>], who advocate that potential neuroprotective agents for the treatment of PD should be tested under conditions that are relevant to the clinical situation. Because clinical symptoms of PD are apparent only after the majority of nigrostriatal neurons have died, patients do not present for treatment until after the process of cell death is well established [<xref ref-type="bibr" rid="CR38">38</xref>]. Most in vitro studies have been conducted by adding potential neuroprotective agents to cells prior to MPP<sup>+</sup>-triggered apoptosis [<xref ref-type="bibr" rid="CR69">69</xref>&#x2013;<xref ref-type="bibr" rid="CR71">71</xref>] or at the same time as MPP<sup>+</sup> [<xref ref-type="bibr" rid="CR27">27</xref>, <xref ref-type="bibr" rid="CR72">72</xref>, <xref ref-type="bibr" rid="CR73">73</xref>], making these results irrelevant to the treatment of PD, where the process of neurodegeneration has already begun.</p>
      <p>Addition of guanosine to cells <italic>after</italic> MPP<sup>+</sup>-induced DNA fragmentation is already in progress may involve additional protective mechanisms. As DNA fragmentation is a late event in apoptosis [<xref ref-type="bibr" rid="CR11">11</xref>, <xref ref-type="bibr" rid="CR12">12</xref>], some cells with damaged DNA may actually undergo DNA repair and survive [<xref ref-type="bibr" rid="CR74">74</xref>, <xref ref-type="bibr" rid="CR75">75</xref>]. The preferred survival strategy of a cell is to attempt to restore any DNA damage by using a complex set of DNA repair pathways [<xref ref-type="bibr" rid="CR74">74</xref>]. Only when the damage to the DNA becomes excessive and the repair capacity of the cell is overwhelmed will it undergo apoptosis. Therefore, adding guanosine 24 or 48&#xA0;h after DNA fragmentation has been initiated may activate some of the DNA repair mechanisms, antagonizing and reversing the MPP<sup>+</sup>-induced DNA fragmentation. The protective effects of guanosine in these cells thus may include activation of both cell survival and DNA repair pathways.</p>
      <p>In contrast, <italic>post-treatment</italic> with guanosine had no significant effect on MPP<sup>+</sup>-induced activation of caspase-3. As activation of this enzyme requires a cleavage of the interdomain region of the inactive dimer of caspase-3, once this process is initiated it cannot be reversed [<xref ref-type="bibr" rid="CR8">8</xref>&#x2013;<xref ref-type="bibr" rid="CR10">10</xref>]. So addition of guanosine to cells after proteolytic cleavage of this enzyme will not alter caspase-3 activity.</p>
      <p>Recently administration of MPTP to mice has been reported to promote caspase-independent cell death of dopaminergic neurons [<xref ref-type="bibr" rid="CR76">76</xref>]. This &#x201C;apoptosis-like&#x201D; programmed cell death [<xref ref-type="bibr" rid="CR77">77</xref>] is mediated by the release of the apoptosis-inducing factor (AIF) from the mitochondria and its subsequent translocation to the nucleus, where it induces DNA fragmentation [<xref ref-type="bibr" rid="CR78">78</xref>&#x2013;<xref ref-type="bibr" rid="CR80">80</xref>]. If this process plays a significant role in MPP<sup>+</sup>-induced cell death of neuroblastoma cells, DNA fragmentation will still be reversed by the protective action of guanosine, but caspase-3 activation will not be affected.</p>
      <p>Several authors suggested recently that targeting programmed cell death in neurodegenerative diseases may lead to successful therapy [<xref ref-type="bibr" rid="CR5">5</xref>, <xref ref-type="bibr" rid="CR31">31</xref>]. Drugs that will be effective in PD should protect the dopaminergic cells from apoptotic insult by either interrupting the signaling pathways that mediate cell death or activating the cell survival pathways. Our present results show that the non-adenine-based purine nucleoside guanosine, when added to MPP<sup>+</sup>-treated neuroblastoma cells, promotes their survival by inhibiting caspase-3 activation and DNA fragmentation via activation of the PI-3-K/Akt/PKB pathway. Furthermore, guanosine exerts these effects not only when it is pre- or co-administered with MPP<sup>+</sup>, but even when it is added to cells <italic>after</italic> caspase-3 is activated and DNA fragmentation is already in progress. Thus, these findings reveal a unique neuroprotective effect of guanosine with a potential for effective pharmacological intervention in PD.</p>
    </sec>
  </body>
  <back>
    <ack>
      <title>Acknowledgements</title>
      <p>This research was supported by a pilot grant from the Parkinson Society Canada to MPR and ESW. KP is a recipient of an Ontario Graduate Studentship (OGS), and an NSERC Graduate Studentship, SJ holds a Brian Keown and Chris Beehler Career Award of the Canadian Spinal Research Organization. The authors would like to thank Dr. Raelene Kinlough-Rathbone for her helpful discussion of the manuscript.</p>
    </ack>
    <ref-list id="Bib1">
      <title>References</title>
      <ref id="CR1">
        <label>1.</label>
        <citation citation-type="other">Birkmayer W, Hornykiewicz O (1961) The effect of L-3,3-dihydroxyphenylalanine (L-DOPA) on akinesia in Parkinsonism. Wien Klin Wochenschr 73:787&#x2013;788. English translation 1998, Parkinsonism and Related Disorders 4:59&#x2013;60</citation>
      </ref>
      <ref id="CR2">
        <label>2.</label>
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Dauer</surname>
              <given-names>W</given-names>
            </name>
            <name>
              <surname>Przedborski</surname>
              <given-names>S</given-names>
            </name>
          </person-group>
          <article-title>Parkinson&#x2019;s disease: Mechanisms and models</article-title>
          <source>Neuron</source>
          <year>2003</year>
          <volume>39</volume>
          <fpage>889</fpage>
          <lpage>909</lpage>
          <pub-id pub-id-type="doi">10.1016/S0896-6273(03)00568-3</pub-id>
        </citation>
        <citation citation-type="display-unstructured">Dauer W, Przedborski S (2003) Parkinson&#x2019;s disease: Mechanisms and models. Neuron 39:889&#x2013;909 <pub-id pub-id-type="pmid">12971891</pub-id></citation>
      </ref>
      <ref id="CR3">
        <label>3.</label>
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Kroemer</surname>
              <given-names>G</given-names>
            </name>
            <name>
              <surname>El-Deiry</surname>
              <given-names>WS</given-names>
            </name>
            <name>
              <surname>Golstein</surname>
              <given-names>P</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>Nomenclature Committee on Cell Death. Classification of cell death: recommendations of the Nomenclature Committee on Cell Death</article-title>
          <source>Cell Death Differ</source>
          <year>2005</year>
          <volume>12</volume>
          <issue>S2</issue>
          <fpage>1463</fpage>
          <lpage>1467</lpage>
          <pub-id pub-id-type="doi">10.1038/sj.cdd.4401724</pub-id>
        </citation>
        <citation citation-type="display-unstructured">Kroemer G, El-Deiry WS, Golstein P et al (2005) Nomenclature Committee on Cell Death. Classification of cell death: recommendations of the Nomenclature Committee on Cell Death. Cell Death Differ 12(S2):1463&#x2013;1467 <pub-id pub-id-type="pmid">16247491</pub-id></citation>
      </ref>
      <ref id="CR4">
        <label>4.</label>
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Olanow</surname>
              <given-names>CW</given-names>
            </name>
            <name>
              <surname>Tatton</surname>
              <given-names>WG</given-names>
            </name>
          </person-group>
          <article-title>Etiology and pathogenesis of Parkinson&#x2019;s disease</article-title>
          <source>Annu Rev Neurosci</source>
          <year>1999</year>
          <volume>22</volume>
          <fpage>123</fpage>
          <lpage>144</lpage>
          <pub-id pub-id-type="doi">10.1146/annurev.neuro.22.1.123</pub-id>
        </citation>
        <citation citation-type="display-unstructured">Olanow CW, Tatton WG (1999) Etiology and pathogenesis of Parkinson&#x2019;s disease. Annu Rev Neurosci 22:123&#x2013;144 <pub-id pub-id-type="pmid">10202534</pub-id></citation>
      </ref>
      <ref id="CR5">
        <label>5.</label>
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Vila</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Przedborski</surname>
              <given-names>S</given-names>
            </name>
          </person-group>
          <article-title>Targeting programmed cell death in neurodegenerative diseases</article-title>
          <source>Nat Rev Neurosci</source>
          <year>2003</year>
          <volume>4</volume>
          <fpage>365</fpage>
          <lpage>375</lpage>
          <pub-id pub-id-type="doi">10.1038/nrn1100</pub-id>
        </citation>
        <citation citation-type="display-unstructured">Vila M, Przedborski S (2003) Targeting programmed cell death in neurodegenerative diseases. Nat Rev Neurosci 4:365&#x2013;375 <pub-id pub-id-type="pmid">12728264</pub-id></citation>
      </ref>
      <ref id="CR6">
        <label>6.</label>
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Bredesen</surname>
              <given-names>DE</given-names>
            </name>
            <name>
              <surname>Rao</surname>
              <given-names>RV</given-names>
            </name>
            <name>
              <surname>Mehlen</surname>
              <given-names>P</given-names>
            </name>
          </person-group>
          <article-title>Cell death in the nervous system</article-title>
          <source>Nature</source>
          <year>2006</year>
          <volume>443</volume>
          <fpage>796</fpage>
          <lpage>802</lpage>
          <pub-id pub-id-type="doi">10.1038/nature05293</pub-id>
        </citation>
        <citation citation-type="display-unstructured">Bredesen DE, Rao RV, Mehlen P (2006) Cell death in the nervous system. Nature 443:796&#x2013;802 <pub-id pub-id-type="pmid">17051206</pub-id></citation>
      </ref>
      <ref id="CR7">
        <label>7.</label>
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Benn</surname>
              <given-names>SC</given-names>
            </name>
            <name>
              <surname>Woolf</surname>
              <given-names>CJ</given-names>
            </name>
          </person-group>
          <article-title>Adult neuron survival strategies&#x2014;slamming on the brakes</article-title>
          <source>Nat Neurosci</source>
          <year>2004</year>
          <volume>5</volume>
          <fpage>686</fpage>
          <lpage>700</lpage>
          <pub-id pub-id-type="doi">10.1038/nrn1477</pub-id>
        </citation>
        <citation citation-type="display-unstructured">Benn SC, Woolf CJ (2004) Adult neuron survival strategies&#x2014;slamming on the brakes. Nat Neurosci 5:686&#x2013;700 </citation>
      </ref>
      <ref id="CR8">
        <label>8.</label>
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Shiozaki</surname>
              <given-names>EN</given-names>
            </name>
            <name>
              <surname>Shi</surname>
              <given-names>Y</given-names>
            </name>
          </person-group>
          <article-title>Caspases, IAPs and Smac/DIABLO: mechanisms from structural biology</article-title>
          <source>Trends Biochem Sci</source>
          <year>2004</year>
          <volume>29</volume>
          <fpage>486</fpage>
          <lpage>494</lpage>
          <pub-id pub-id-type="doi">10.1016/j.tibs.2004.07.003</pub-id>
        </citation>
        <citation citation-type="display-unstructured">Shiozaki EN, Shi Y (2004) Caspases, IAPs and Smac/DIABLO: mechanisms from structural biology. Trends Biochem Sci 29:486&#x2013;494 <pub-id pub-id-type="pmid">15337122</pub-id></citation>
      </ref>
      <ref id="CR9">
        <label>9.</label>
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Boatright</surname>
              <given-names>KM</given-names>
            </name>
            <name>
              <surname>Salvesen</surname>
              <given-names>GS</given-names>
            </name>
          </person-group>
          <article-title>Mechanisms of caspase activation</article-title>
          <source>Curr Opin Cell Biol</source>
          <year>2003</year>
          <volume>15</volume>
          <fpage>725</fpage>
          <lpage>731</lpage>
          <pub-id pub-id-type="doi">10.1016/j.ceb.2003.10.009</pub-id>
        </citation>
        <citation citation-type="display-unstructured">Boatright KM, Salvesen GS (2003) Mechanisms of caspase activation. Curr Opin Cell Biol 15:725&#x2013;731 <pub-id pub-id-type="pmid">14644197</pub-id></citation>
      </ref>
      <ref id="CR10">
        <label>10.</label>
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Kumar</surname>
              <given-names>S</given-names>
            </name>
          </person-group>
          <article-title>Caspase function in programmed cell death</article-title>
          <source>Cell Death Differ</source>
          <year>2007</year>
          <volume>14</volume>
          <fpage>32</fpage>
          <lpage>43</lpage>
          <pub-id pub-id-type="doi">10.1038/sj.cdd.4402060</pub-id>
        </citation>
        <citation citation-type="display-unstructured">Kumar S (2007) Caspase function in programmed cell death. Cell Death Differ 14:32&#x2013;43 <pub-id pub-id-type="pmid">17082813</pub-id></citation>
      </ref>
      <ref id="CR11">
        <label>11.</label>
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Nagata</surname>
              <given-names>S</given-names>
            </name>
          </person-group>
          <article-title>Apoptotic DNA fragmentation</article-title>
          <source>Exp Cell Res</source>
          <year>2000</year>
          <volume>256</volume>
          <fpage>12</fpage>
          <lpage>18</lpage>
          <pub-id pub-id-type="doi">10.1006/excr.2000.4834</pub-id>
        </citation>
        <citation citation-type="display-unstructured">Nagata S (2000) Apoptotic DNA fragmentation. Exp Cell Res 256:12&#x2013;18 <pub-id pub-id-type="pmid">10739646</pub-id></citation>
      </ref>
      <ref id="CR12">
        <label>12.</label>
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Nagata</surname>
              <given-names>S</given-names>
            </name>
          </person-group>
          <article-title>DNA degradation in development and programmed cell death</article-title>
          <source>Annu Rev Immunol</source>
          <year>2005</year>
          <volume>23</volume>
          <fpage>853</fpage>
          <lpage>875</lpage>
          <pub-id pub-id-type="doi">10.1146/annurev.immunol.23.021704.115811</pub-id>
        </citation>
        <citation citation-type="display-unstructured">Nagata S (2005) DNA degradation in development and programmed cell death. Annu Rev Immunol 23:853&#x2013;875 <pub-id pub-id-type="pmid">15771588</pub-id></citation>
      </ref>
      <ref id="CR13">
        <label>13.</label>
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Hartmann</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>Hunot</surname>
              <given-names>S</given-names>
            </name>
            <name>
              <surname>Michel</surname>
              <given-names>PP</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>Caspase-3: a vulnerability factor and final effector in apoptotic death of dopaminergic neurons in Parkinson&#x2019;s disease</article-title>
          <source>Proc Natl Acad Sci U S A</source>
          <year>2000</year>
          <volume>97</volume>
          <fpage>2875</fpage>
          <lpage>2880</lpage>
          <pub-id pub-id-type="doi">10.1073/pnas.040556597</pub-id>
        </citation>
        <citation citation-type="display-unstructured">Hartmann A, Hunot S, Michel PP et al (2000) Caspase-3: a vulnerability factor and final effector in apoptotic death of dopaminergic neurons in Parkinson&#x2019;s disease. Proc Natl Acad Sci U S A 97:2875&#x2013;2880 <pub-id pub-id-type="pmid">10688892</pub-id></citation>
      </ref>
      <ref id="CR14">
        <label>14.</label>
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Tatton</surname>
              <given-names>NA</given-names>
            </name>
          </person-group>
          <article-title>Increased caspase 3 and Bax immunoreactivity accompany nuclear GAPDH translocation and neuronal apoptosis in Parkinson&#x2019;s disease</article-title>
          <source>Exp Neurol</source>
          <year>2000</year>
          <volume>166</volume>
          <fpage>29</fpage>
          <lpage>43</lpage>
          <pub-id pub-id-type="doi">10.1006/exnr.2000.7489</pub-id>
        </citation>
        <citation citation-type="display-unstructured">Tatton NA (2000) Increased caspase 3 and Bax immunoreactivity accompany nuclear GAPDH translocation and neuronal apoptosis in Parkinson&#x2019;s disease. Exp Neurol 166:29&#x2013;43 <pub-id pub-id-type="pmid">11031081</pub-id></citation>
      </ref>
      <ref id="CR15">
        <label>15.</label>
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Hartmann</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>Michel</surname>
              <given-names>PP</given-names>
            </name>
            <name>
              <surname>Troadec</surname>
              <given-names>J-D</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>Is Bax a mitochondrial mediator of apoptotic death of dopaminergic neurons in Parkinson&#x2019;s disease?</article-title>
          <source>J Neurochem</source>
          <year>2001</year>
          <volume>76</volume>
          <fpage>1785</fpage>
          <lpage>1793</lpage>
          <pub-id pub-id-type="doi">10.1046/j.1471-4159.2001.00160.x</pub-id>
        </citation>
        <citation citation-type="display-unstructured">Hartmann A, Michel PP, Troadec J-D et al (2001) Is Bax a mitochondrial mediator of apoptotic death of dopaminergic neurons in Parkinson&#x2019;s disease? J Neurochem 76:1785&#x2013;1793 <pub-id pub-id-type="pmid">11259496</pub-id></citation>
      </ref>
      <ref id="CR16">
        <label>16.</label>
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Przedborski</surname>
              <given-names>S</given-names>
            </name>
            <name>
              <surname>Vila</surname>
              <given-names>M</given-names>
            </name>
          </person-group>
          <article-title>The 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine mouse model: a tool to explore the pathogenesis of Parkinson&#x2019;s disease</article-title>
          <source>Ann N Y Acad Sci</source>
          <year>2003</year>
          <volume>991</volume>
          <fpage>189</fpage>
          <lpage>198</lpage>
        </citation>
        <citation citation-type="display-unstructured">Przedborski S, Vila M (2003) The 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine mouse model: a tool to explore the pathogenesis of Parkinson&#x2019;s disease. Ann N Y Acad Sci 991:189&#x2013;198 <pub-id pub-id-type="pmid">12846987</pub-id></citation>
      </ref>
      <ref id="CR17">
        <label>17.</label>
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Smeyne</surname>
              <given-names>RJ</given-names>
            </name>
            <name>
              <surname>Jackson-Lewis</surname>
              <given-names>V</given-names>
            </name>
          </person-group>
          <article-title>The MPTP model of Parkinson&#x2019;s disease</article-title>
          <source>Mol Brain Res</source>
          <year>2005</year>
          <volume>134</volume>
          <fpage>57</fpage>
          <lpage>66</lpage>
          <pub-id pub-id-type="doi">10.1016/j.molbrainres.2004.09.017</pub-id>
        </citation>
        <citation citation-type="display-unstructured">Smeyne RJ, Jackson-Lewis V (2005) The MPTP model of Parkinson&#x2019;s disease. Mol Brain Res 134:57&#x2013;66 <pub-id pub-id-type="pmid">15790530</pub-id></citation>
      </ref>
      <ref id="CR18">
        <label>18.</label>
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Nicotra</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>Pavrez</surname>
              <given-names>SH</given-names>
            </name>
          </person-group>
          <article-title>Cell death induced by MPTP, a substrate for monoamine oxidase B</article-title>
          <source>Toxicology</source>
          <year>2000</year>
          <volume>153</volume>
          <fpage>157</fpage>
          <lpage>166</lpage>
          <pub-id pub-id-type="doi">10.1016/S0300-483X(00)00311-5</pub-id>
        </citation>
        <citation citation-type="display-unstructured">Nicotra A, Pavrez SH (2000) Cell death induced by MPTP, a substrate for monoamine oxidase B. Toxicology 153:157&#x2013;166 <pub-id pub-id-type="pmid">11090954</pub-id></citation>
      </ref>
      <ref id="CR19">
        <label>19.</label>
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Fornai</surname>
              <given-names>F</given-names>
            </name>
            <name>
              <surname>Schluter</surname>
              <given-names>OM</given-names>
            </name>
            <name>
              <surname>Lenzi</surname>
              <given-names>P</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>Parkinson-like syndrome induced by continuous MPTP infusion: convergent roles of the ubiquitin-proteasome system and alpha-synuclein</article-title>
          <source>Proc Natl Acad Sci U S A</source>
          <year>2005</year>
          <volume>102</volume>
          <fpage>3413</fpage>
          <lpage>3418</lpage>
          <pub-id pub-id-type="doi">10.1073/pnas.0409713102</pub-id>
        </citation>
        <citation citation-type="display-unstructured">Fornai F, Schluter OM, Lenzi P et al (2005) Parkinson-like syndrome induced by continuous MPTP infusion: convergent roles of the ubiquitin-proteasome system and alpha-synuclein. Proc Natl Acad Sci U S A 102:3413&#x2013;3418 <pub-id pub-id-type="pmid">15716361</pub-id></citation>
      </ref>
      <ref id="CR20">
        <label>20.</label>
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Lin</surname>
              <given-names>MT</given-names>
            </name>
            <name>
              <surname>Beal</surname>
              <given-names>MF</given-names>
            </name>
          </person-group>
          <article-title>Mitochondrial dysfunction and oxidative stress in neurodegenerative diseases</article-title>
          <source>Nature</source>
          <year>2006</year>
          <volume>443</volume>
          <fpage>787</fpage>
          <lpage>795</lpage>
          <pub-id pub-id-type="doi">10.1038/nature05292</pub-id>
        </citation>
        <citation citation-type="display-unstructured">Lin MT, Beal MF (2006) Mitochondrial dysfunction and oxidative stress in neurodegenerative diseases. Nature 443:787&#x2013;795 <pub-id pub-id-type="pmid">17051205</pub-id></citation>
      </ref>
      <ref id="CR21">
        <label>21.</label>
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Tatton</surname>
              <given-names>NA</given-names>
            </name>
            <name>
              <surname>Kish</surname>
              <given-names>SJ</given-names>
            </name>
          </person-group>
          <article-title>In situ detection of apoptotic nuclei in the substantia nigra compacta of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-treated mice using terminal deoxynucleotidyl transferase labelling and acridine orange staining</article-title>
          <source>Neuroscience</source>
          <year>1997</year>
          <volume>77</volume>
          <fpage>1037</fpage>
          <lpage>1048</lpage>
          <pub-id pub-id-type="doi">10.1016/S0306-4522(96)00545-3</pub-id>
        </citation>
        <citation citation-type="display-unstructured">Tatton NA, Kish SJ (1997) In situ detection of apoptotic nuclei in the substantia nigra compacta of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-treated mice using terminal deoxynucleotidyl transferase labelling and acridine orange staining. Neuroscience 77:1037&#x2013;1048 <pub-id pub-id-type="pmid">9130785</pub-id></citation>
      </ref>
      <ref id="CR22">
        <label>22.</label>
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Maries</surname>
              <given-names>E</given-names>
            </name>
            <name>
              <surname>Dass</surname>
              <given-names>B</given-names>
            </name>
            <name>
              <surname>Collier</surname>
              <given-names>TJ</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>The role of alpha-synuclein in Parkinson&#x2019;s disease: insights from animal models</article-title>
          <source>Nat Rev Neurosci</source>
          <year>2003</year>
          <volume>4</volume>
          <fpage>727</fpage>
          <lpage>738</lpage>
          <pub-id pub-id-type="doi">10.1038/nrn1199</pub-id>
        </citation>
        <citation citation-type="display-unstructured">Maries E, Dass B, Collier TJ et al (2003) The role of alpha-synuclein in Parkinson&#x2019;s disease: insights from animal models. Nat Rev Neurosci 4:727&#x2013;738 <pub-id pub-id-type="pmid">12951565</pub-id></citation>
      </ref>
      <ref id="CR23">
        <label>23.</label>
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>G&#xF3;mez</surname>
              <given-names>C</given-names>
            </name>
            <name>
              <surname>Reiriz</surname>
              <given-names>J</given-names>
            </name>
            <name>
              <surname>Pique</surname>
              <given-names>M</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>Low concentrations of 1-methyl-4-phenylpyridinium ion induce caspase-mediated apoptosis in human SH-SY5Y neuroblastoma cells</article-title>
          <source>J Neurosci Res</source>
          <year>2001</year>
          <volume>63</volume>
          <fpage>421</fpage>
          <lpage>428</lpage>
          <pub-id pub-id-type="doi">10.1002/1097-4547(20010301)63:5&lt;421::AID-JNR1037&gt;3.0.CO;2-4</pub-id>
        </citation>
        <citation citation-type="display-unstructured">G&#xF3;mez C, Reiriz J, Pique M et al (2001) Low concentrations of 1-methyl-4-phenylpyridinium ion induce caspase-mediated apoptosis in human SH-SY5Y neuroblastoma cells. J Neurosci Res 63:421&#x2013;428 <pub-id pub-id-type="pmid">11223917</pub-id></citation>
      </ref>
      <ref id="CR24">
        <label>24.</label>
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Fall</surname>
              <given-names>CP</given-names>
            </name>
            <name>
              <surname>Bennett</surname>
              <given-names>JP</given-names>
            </name>
          </person-group>
          <article-title>Characterization and time course of MPP<sup>+</sup>-induced apoptosis in human SH-SY5Y neuroblastoma cells</article-title>
          <source>J Neurosci Res</source>
          <year>1999</year>
          <volume>55</volume>
          <fpage>620</fpage>
          <lpage>628</lpage>
          <pub-id pub-id-type="doi">10.1002/(SICI)1097-4547(19990301)55:5&lt;620::AID-JNR9&gt;3.0.CO;2-S</pub-id>
        </citation>
        <citation citation-type="display-unstructured">Fall CP, Bennett JP Jr (1999) Characterization and time course of MPP+-induced apoptosis in human SH-SY5Y neuroblastoma cells. J Neurosci Res 55:620&#x2013;628 <pub-id pub-id-type="pmid">10082084</pub-id></citation>
      </ref>
      <ref id="CR25">
        <label>25.</label>
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Itano</surname>
              <given-names>Y</given-names>
            </name>
            <name>
              <surname>Nomura</surname>
              <given-names>Y</given-names>
            </name>
          </person-group>
          <article-title>1-Methyl-4-phenyl-pyridinium ion (MPP<sup>+</sup>) causes DNA fragmentation and increases the Bcl-2 expression in human neuroblastoma, SH-SY5Y cells, through different mechanisms</article-title>
          <source>Brain Res</source>
          <year>1995</year>
          <volume>704</volume>
          <fpage>240</fpage>
          <lpage>245</lpage>
          <pub-id pub-id-type="doi">10.1016/0006-8993(95)01120-X</pub-id>
        </citation>
        <citation citation-type="display-unstructured">Itano Y, Nomura Y (1995) 1-Methyl-4-phenyl-pyridinium ion (MPP+) causes DNA fragmentation and increases the Bcl-2 expression in human neuroblastoma, SH-SY5Y cells, through different mechanisms. Brain Res 704:240&#x2013;245 <pub-id pub-id-type="pmid">8788920</pub-id></citation>
      </ref>
      <ref id="CR26">
        <label>26.</label>
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>King</surname>
              <given-names>TD</given-names>
            </name>
            <name>
              <surname>Bijur</surname>
              <given-names>GN</given-names>
            </name>
            <name>
              <surname>Jope</surname>
              <given-names>RS</given-names>
            </name>
          </person-group>
          <article-title>Caspase-3 activation induced by inhibition of mitochondrial complex I is facilitated by glycogen synthase kinase-3&#x3B2; and attenuated by lithium</article-title>
          <source>Brain Res</source>
          <year>2001</year>
          <volume>919</volume>
          <fpage>106</fpage>
          <lpage>114</lpage>
          <pub-id pub-id-type="doi">10.1016/S0006-8993(01)03005-0</pub-id>
        </citation>
        <citation citation-type="display-unstructured">King TD, Bijur GN, Jope RS (2001) Caspase-3 activation induced by inhibition of mitochondrial complex I is facilitated by glycogen synthase kinase-3&#x3B2; and attenuated by lithium. Brain Res 919:106&#x2013;114 <pub-id pub-id-type="pmid">11689167</pub-id></citation>
      </ref>
      <ref id="CR27">
        <label>27.</label>
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Kakimura</surname>
              <given-names>J</given-names>
            </name>
            <name>
              <surname>Kitamura</surname>
              <given-names>Y</given-names>
            </name>
            <name>
              <surname>Takata</surname>
              <given-names>K</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>Release and aggregation of cytochrome c and [alpha]-synuclein are inhibited by the antiparkinsonian drugs, talipexole and pramipexole</article-title>
          <source>Eur J Pharmacol</source>
          <year>2001</year>
          <volume>417</volume>
          <fpage>59</fpage>
          <lpage>67</lpage>
          <pub-id pub-id-type="doi">10.1016/S0014-2999(01)00902-5</pub-id>
        </citation>
        <citation citation-type="display-unstructured">Kakimura J, Kitamura Y, Takata K et al (2001) Release and aggregation of cytochrome c and [alpha]-synuclein are inhibited by the antiparkinsonian drugs, talipexole and pramipexole. Eur J Pharmacol 417:59&#x2013;67 <pub-id pub-id-type="pmid">11301060</pub-id></citation>
      </ref>
      <ref id="CR28">
        <label>28.</label>
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>G&#xF3;mez-Santos</surname>
              <given-names>C</given-names>
            </name>
            <name>
              <surname>Ferrer</surname>
              <given-names>I</given-names>
            </name>
            <name>
              <surname>Reiriz</surname>
              <given-names>J</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>MPP<sup>+</sup> increases &#x3B1;-synuclein expression and ERK/MAP-kinase phosphorylation in human neuroblastoma SH-SY5Y cells</article-title>
          <source>Brain Res</source>
          <year>2002</year>
          <volume>935</volume>
          <fpage>32</fpage>
          <lpage>39</lpage>
          <pub-id pub-id-type="doi">10.1016/S0006-8993(02)02422-8</pub-id>
        </citation>
        <citation citation-type="display-unstructured">G&#xF3;mez-Santos C, Ferrer I, Reiriz J et al (2002) MPP+ increases &#x3B1;-synuclein expression and ERK/MAP-kinase phosphorylation in human neuroblastoma SH-SY5Y cells. Brain Res 935:32&#x2013;39 <pub-id pub-id-type="pmid">12062470</pub-id></citation>
      </ref>
      <ref id="CR29">
        <label>29.</label>
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Kalivendi</surname>
              <given-names>SV</given-names>
            </name>
            <name>
              <surname>Cunningham</surname>
              <given-names>S</given-names>
            </name>
            <name>
              <surname>Kotamraju</surname>
              <given-names>S</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>&#x3B1;-Synuclein up-regulation and aggregation during MPP<sup>+</sup>-induced apoptosis in neuroblastoma cells</article-title>
          <source>J Biol Chem</source>
          <year>2004</year>
          <volume>279</volume>
          <fpage>15240</fpage>
          <lpage>15247</lpage>
          <pub-id pub-id-type="doi">10.1074/jbc.M312497200</pub-id>
        </citation>
        <citation citation-type="display-unstructured">Kalivendi SV, Cunningham S, Kotamraju S et al (2004) &#x3B1;-Synuclein up-regulation and aggregation during MPP+-induced apoptosis in neuroblastoma cells. J Biol Chem 279:15240&#x2013;15247 <pub-id pub-id-type="pmid">14742448</pub-id></citation>
      </ref>
      <ref id="CR30">
        <label>30.</label>
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Xu</surname>
              <given-names>J</given-names>
            </name>
            <name>
              <surname>Kao</surname>
              <given-names>SY</given-names>
            </name>
            <name>
              <surname>Lee</surname>
              <given-names>FJ</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>Dopamine-dependent neurotoxicity of alpha-synuclein: a mechanism for selective neurodegeneration in Parkinson disease</article-title>
          <source>Nat Med</source>
          <year>2002</year>
          <volume>8</volume>
          <fpage>600</fpage>
          <lpage>606</lpage>
          <pub-id pub-id-type="doi">10.1038/nm0602-600</pub-id>
        </citation>
        <citation citation-type="display-unstructured">Xu J, Kao SY, Lee FJ et al (2002) Dopamine-dependent neurotoxicity of alpha-synuclein: a mechanism for selective neurodegeneration in Parkinson disease. Nat Med 8:600&#x2013;606 <pub-id pub-id-type="pmid">12042811</pub-id></citation>
      </ref>
      <ref id="CR31">
        <label>31.</label>
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Waldmeier</surname>
              <given-names>PC</given-names>
            </name>
            <name>
              <surname>Tatton</surname>
              <given-names>WG</given-names>
            </name>
          </person-group>
          <article-title>Interrupting apoptosis in neurodegenerative disease: potential for effective therapy?</article-title>
          <source>Drug Discov Today</source>
          <year>2004</year>
          <volume>9</volume>
          <fpage>210</fpage>
          <lpage>218</lpage>
          <pub-id pub-id-type="doi">10.1016/S1359-6446(03)03000-9</pub-id>
        </citation>
        <citation citation-type="display-unstructured">Waldmeier PC, Tatton WG (2004) Interrupting apoptosis in neurodegenerative disease: potential for effective therapy? Drug Discov Today 9:210&#x2013;218 <pub-id pub-id-type="pmid">14980539</pub-id></citation>
      </ref>
      <ref id="CR32">
        <label>32.</label>
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Rathbone</surname>
              <given-names>MP</given-names>
            </name>
            <name>
              <surname>Middlemiss</surname>
              <given-names>PJ</given-names>
            </name>
            <name>
              <surname>Gysbers</surname>
              <given-names>JW</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>Trophic effects of purines in neurons and glial cells</article-title>
          <source>Prog Neurobiol</source>
          <year>1999</year>
          <volume>59</volume>
          <fpage>663</fpage>
          <lpage>690</lpage>
          <pub-id pub-id-type="doi">10.1016/S0301-0082(99)00017-9</pub-id>
        </citation>
        <citation citation-type="display-unstructured">Rathbone MP, Middlemiss PJ, Gysbers JW et al (1999) Trophic effects of purines in neurons and glial cells. Prog Neurobiol 59:663&#x2013;690 <pub-id pub-id-type="pmid">10845757</pub-id></citation>
      </ref>
      <ref id="CR33">
        <label>33.</label>
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Iorio</surname>
              <given-names>P</given-names>
            </name>
            <name>
              <surname>Ballerini</surname>
              <given-names>P</given-names>
            </name>
            <name>
              <surname>Traversa</surname>
              <given-names>U</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>The anti-apoptotic effect of guanosine is mediated by the activation of the PI 3-kinase/AKT/PKB pathway in cultured rat astrocytes</article-title>
          <source>Glia</source>
          <year>2004</year>
          <volume>46</volume>
          <fpage>356</fpage>
          <lpage>368</lpage>
          <pub-id pub-id-type="doi">10.1002/glia.20002</pub-id>
        </citation>
        <citation citation-type="display-unstructured">Di Iorio P, Ballerini P, Traversa U et al (2004) The anti-apoptotic effect of guanosine is mediated by the activation of the PI 3-kinase/AKT/PKB pathway in cultured rat astrocytes. Glia 46:356&#x2013;368 <pub-id pub-id-type="pmid">15095366</pub-id></citation>
      </ref>
      <ref id="CR34">
        <label>34.</label>
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Pettifer</surname>
              <given-names>KM</given-names>
            </name>
            <name>
              <surname>Kleywegt</surname>
              <given-names>S</given-names>
            </name>
            <name>
              <surname>Bau</surname>
              <given-names>CJ</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>Guanosine protects SH-SY5Y neuroblastoma cells against &#x3B2;-amyloid-induced apoptosis</article-title>
          <source>Neuroreport</source>
          <year>2004</year>
          <volume>15</volume>
          <fpage>833</fpage>
          <lpage>836</lpage>
          <pub-id pub-id-type="doi">10.1097/00001756-200404090-00019</pub-id>
        </citation>
        <citation citation-type="display-unstructured">Pettifer KM, Kleywegt S, Bau CJ et al (2004) Guanosine protects SH-SY5Y neuroblastoma cells against &#x3B2;-amyloid-induced apoptosis. Neuroreport 15:833&#x2013;836 <pub-id pub-id-type="pmid">15073525</pub-id></citation>
      </ref>
      <ref id="CR35">
        <label>35.</label>
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Traversa</surname>
              <given-names>U</given-names>
            </name>
            <name>
              <surname>Bombi</surname>
              <given-names>G</given-names>
            </name>
            <name>
              <surname>Iorio</surname>
              <given-names>P</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>Specific [H<sup>3</sup>]-guanosine binding sites in rat brain membranes</article-title>
          <source>Br J Pharmacol</source>
          <year>2002</year>
          <volume>135</volume>
          <fpage>969</fpage>
          <lpage>976</lpage>
          <pub-id pub-id-type="doi">10.1038/sj.bjp.0704542</pub-id>
        </citation>
        <citation citation-type="display-unstructured">Traversa U, Bombi G, Di Iorio P et al (2002) Specific [H3]-guanosine binding sites in rat brain membranes. Br J Pharmacol 135:969&#x2013;976 <pub-id pub-id-type="pmid">11861325</pub-id></citation>
      </ref>
      <ref id="CR36">
        <label>36.</label>
        <citation citation-type="other">Traversa U, Di Iorio P, Palmieri C et al (2002) Identification of a guanosine receptor linked to the modulation of adenylate cyclase and MAPK activity in primary cultures of rat astrocytes. Presentation Riunione Annuale del Purine Club 27 October 2002</citation>
      </ref>
      <ref id="CR37">
        <label>37.</label>
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Traversa</surname>
              <given-names>U</given-names>
            </name>
            <name>
              <surname>Bombi</surname>
              <given-names>G</given-names>
            </name>
            <name>
              <surname>Camaioni</surname>
              <given-names>E</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>Rat brain guanosine binding site. Biological studies and pseudo-receptor construction</article-title>
          <source>Bioorg Med Chem</source>
          <year>2003</year>
          <volume>11</volume>
          <fpage>5417</fpage>
          <lpage>5425</lpage>
          <pub-id pub-id-type="doi">10.1016/j.bmc.2003.09.043</pub-id>
        </citation>
        <citation citation-type="display-unstructured">Traversa U, Bombi G, Camaioni E et al (2003) Rat brain guanosine binding site. Biological studies and pseudo-receptor construction. Bioorg Med Chem 11:5417&#x2013;5425 <pub-id pub-id-type="pmid">14642586</pub-id></citation>
      </ref>
      <ref id="CR38">
        <label>38.</label>
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Meissner</surname>
              <given-names>W</given-names>
            </name>
            <name>
              <surname>Hill</surname>
              <given-names>MP</given-names>
            </name>
            <name>
              <surname>Tison</surname>
              <given-names>F</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>Neuroprotective strategies for Parkinson&#x2019;s disease: conceptual limits of animal models and clinical trials</article-title>
          <source>Trends Pharmacol Sci</source>
          <year>2004</year>
          <volume>25</volume>
          <fpage>249</fpage>
          <lpage>253</lpage>
          <pub-id pub-id-type="doi">10.1016/j.tips.2004.03.003</pub-id>
        </citation>
        <citation citation-type="display-unstructured">Meissner W, Hill MP, Tison F et al (2004) Neuroprotective strategies for Parkinson&#x2019;s disease: conceptual limits of animal models and clinical trials. Trends Pharmacol Sci 25:249&#x2013;253 <pub-id pub-id-type="pmid">15120490</pub-id></citation>
      </ref>
      <ref id="CR39">
        <label>39.</label>
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Gavrieli</surname>
              <given-names>Y</given-names>
            </name>
            <name>
              <surname>Sherman</surname>
              <given-names>Y</given-names>
            </name>
            <name>
              <surname>Ben-Sasson</surname>
              <given-names>SA</given-names>
            </name>
          </person-group>
          <article-title>Identification of programmed cell death in situ via specific labeling of nuclear DNA fragmentation</article-title>
          <source>J Cell Biol</source>
          <year>1992</year>
          <volume>119</volume>
          <fpage>493</fpage>
          <lpage>501</lpage>
          <pub-id pub-id-type="doi">10.1083/jcb.119.3.493</pub-id>
        </citation>
        <citation citation-type="display-unstructured">Gavrieli Y, Sherman Y, Ben-Sasson SA (1992) Identification of programmed cell death in situ via specific labeling of nuclear DNA fragmentation. J Cell Biol 119:493&#x2013;501 <pub-id pub-id-type="pmid">1400587</pub-id></citation>
      </ref>
      <ref id="CR40">
        <label>40.</label>
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Iorio</surname>
              <given-names>P</given-names>
            </name>
            <name>
              <surname>Caciagli</surname>
              <given-names>F</given-names>
            </name>
            <name>
              <surname>Giuliani</surname>
              <given-names>P</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>Purine nucleosides protect injured neurons and stimulate neuronal regeneration by intracellular and membrane receptor-mediated mechanisms</article-title>
          <source>Drug Dev Res</source>
          <year>2001</year>
          <volume>52</volume>
          <fpage>303</fpage>
          <lpage>315</lpage>
          <pub-id pub-id-type="doi">10.1002/ddr.1128</pub-id>
        </citation>
        <citation citation-type="display-unstructured">Di Iorio P, Caciagli F, Giuliani P et al (2001) Purine nucleosides protect injured neurons and stimulate neuronal regeneration by intracellular and membrane receptor-mediated mechanisms. Drug Dev Res 52:303&#x2013;315 </citation>
      </ref>
      <ref id="CR41">
        <label>41.</label>
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Viswanath</surname>
              <given-names>V</given-names>
            </name>
            <name>
              <surname>Wu</surname>
              <given-names>Y</given-names>
            </name>
            <name>
              <surname>Boonplueang</surname>
              <given-names>R</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>Caspase-9 activation results in downstream caspase-8 activation and bid cleavage in 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-induced Parkinson&#x2019;s disease</article-title>
          <source>J Neurosci</source>
          <year>2001</year>
          <volume>21</volume>
          <fpage>9519</fpage>
          <lpage>9528</lpage>
        </citation>
        <citation citation-type="display-unstructured">Viswanath V, Wu Y, Boonplueang R et al (2001) Caspase-9 activation results in downstream caspase-8 activation and bid cleavage in 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-induced Parkinson&#x2019;s disease. J Neurosci 21:9519&#x2013;9528 <pub-id pub-id-type="pmid">11739563</pub-id></citation>
      </ref>
      <ref id="CR42">
        <label>42.</label>
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Vila</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Jackson-Lewis</surname>
              <given-names>V</given-names>
            </name>
            <name>
              <surname>Vukosavic</surname>
              <given-names>S</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>Bax ablation prevents dopaminergic neurodegeneration in the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine mouse model of Parkinson&#x2019;s disease</article-title>
          <source>Proc Natl Acad Sci U S A</source>
          <year>2001</year>
          <volume>98</volume>
          <fpage>2837</fpage>
          <lpage>2842</lpage>
          <pub-id pub-id-type="doi">10.1073/pnas.051633998</pub-id>
        </citation>
        <citation citation-type="display-unstructured">Vila M, Jackson-Lewis V, Vukosavic S et al (2001) Bax ablation prevents dopaminergic neurodegeneration in the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine mouse model of Parkinson&#x2019;s disease. Proc Natl Acad Sci U S A 98:2837&#x2013;2842 <pub-id pub-id-type="pmid">11226327</pub-id></citation>
      </ref>
      <ref id="CR43">
        <label>43.</label>
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Polymeropoulos</surname>
              <given-names>MH</given-names>
            </name>
            <name>
              <surname>Lavedan</surname>
              <given-names>C</given-names>
            </name>
            <name>
              <surname>Leroy</surname>
              <given-names>E</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>Mutation in the alpha-synuclein gene identified in families with Parkinson&#x2019;s disease</article-title>
          <source>Science</source>
          <year>1997</year>
          <volume>276</volume>
          <fpage>2045</fpage>
          <lpage>2047</lpage>
          <pub-id pub-id-type="doi">10.1126/science.276.5321.2045</pub-id>
        </citation>
        <citation citation-type="display-unstructured">Polymeropoulos MH, Lavedan C, Leroy E et al (1997) Mutation in the alpha-synuclein gene identified in families with Parkinson&#x2019;s disease. Science 276:2045&#x2013;2047 <pub-id pub-id-type="pmid">9197268</pub-id></citation>
      </ref>
      <ref id="CR44">
        <label>44.</label>
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Spillantini</surname>
              <given-names>MG</given-names>
            </name>
            <name>
              <surname>Schmidt</surname>
              <given-names>ML</given-names>
            </name>
            <name>
              <surname>Lee</surname>
              <given-names>VMY</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>Alpha-synuclein in Lewy bodies</article-title>
          <source>Nature</source>
          <year>1997</year>
          <volume>388</volume>
          <fpage>839</fpage>
          <lpage>840</lpage>
          <pub-id pub-id-type="doi">10.1038/42166</pub-id>
        </citation>
        <citation citation-type="display-unstructured">Spillantini MG, Schmidt ML, Lee VMY et al (1997) Alpha-synuclein in Lewy bodies. Nature 388:839&#x2013;840 <pub-id pub-id-type="pmid">9278044</pub-id></citation>
      </ref>
      <ref id="CR45">
        <label>45.</label>
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Vila</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Vukosavic</surname>
              <given-names>S</given-names>
            </name>
            <name>
              <surname>Jackson-Lewis</surname>
              <given-names>V</given-names>
            </name>
          </person-group>
          <article-title>Alpha-synuclein up-regulation in substantia nigra dopaminergic neurons following administration of the Parkinsonian toxin MPTP</article-title>
          <source>J Neurochem</source>
          <year>2000</year>
          <volume>74</volume>
          <fpage>721</fpage>
          <lpage>729</lpage>
          <pub-id pub-id-type="doi">10.1046/j.1471-4159.2000.740721.x</pub-id>
        </citation>
        <citation citation-type="display-unstructured">Vila M, Vukosavic S, Jackson-Lewis V (2000) Alpha-synuclein up-regulation in substantia nigra dopaminergic neurons following administration of the Parkinsonian toxin MPTP. J Neurochem 74:721&#x2013;729 <pub-id pub-id-type="pmid">10646524</pub-id></citation>
      </ref>
      <ref id="CR46">
        <label>46.</label>
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Katada</surname>
              <given-names>T</given-names>
            </name>
            <name>
              <surname>Ui</surname>
              <given-names>M</given-names>
            </name>
          </person-group>
          <article-title>Direct modification of the membrane adenylate cyclase system by islet-activating protein due to ADP-ribosylation of a membrane protein</article-title>
          <source>Proc Natl Acad Sci U S A</source>
          <year>1982</year>
          <volume>79</volume>
          <fpage>3129</fpage>
          <lpage>3133</lpage>
          <pub-id pub-id-type="doi">10.1073/pnas.79.10.3129</pub-id>
        </citation>
        <citation citation-type="display-unstructured">Katada T, Ui M (1982) Direct modification of the membrane adenylate cyclase system by islet-activating protein due to ADP-ribosylation of a membrane protein. Proc Natl Acad Sci U S A 79:3129&#x2013;3133 <pub-id pub-id-type="pmid">6954463</pub-id></citation>
      </ref>
      <ref id="CR47">
        <label>47.</label>
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Kaslow</surname>
              <given-names>HR</given-names>
            </name>
            <name>
              <surname>Burns</surname>
              <given-names>DL</given-names>
            </name>
          </person-group>
          <article-title>Pertussis toxin and target eukaryotic cells: binding, entry, and activation</article-title>
          <source>FASEB J</source>
          <year>1992</year>
          <volume>6</volume>
          <fpage>2684</fpage>
          <lpage>2690</lpage>
        </citation>
        <citation citation-type="display-unstructured">Kaslow HR, Burns DL (1992) Pertussis toxin and target eukaryotic cells: binding, entry, and activation. FASEB J 6:2684&#x2013;2690 <pub-id pub-id-type="pmid">1612292</pub-id></citation>
      </ref>
      <ref id="CR48">
        <label>48.</label>
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Sunahara</surname>
              <given-names>RK</given-names>
            </name>
            <name>
              <surname>Dessauer</surname>
              <given-names>CW</given-names>
            </name>
            <name>
              <surname>Gilman</surname>
              <given-names>AG</given-names>
            </name>
          </person-group>
          <article-title>Complexity and diversity of mammalian adenylyl cyclases</article-title>
          <source>Annu Rev Pharmacol Toxicol</source>
          <year>1996</year>
          <volume>36</volume>
          <fpage>461</fpage>
          <lpage>480</lpage>
          <pub-id pub-id-type="doi">10.1146/annurev.pa.36.040196.002333</pub-id>
        </citation>
        <citation citation-type="display-unstructured">Sunahara RK, Dessauer CW, Gilman AG (1996) Complexity and diversity of mammalian adenylyl cyclases. Annu Rev Pharmacol Toxicol 36:461&#x2013;480 <pub-id pub-id-type="pmid">8725398</pub-id></citation>
      </ref>
      <ref id="CR49">
        <label>49.</label>
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Milligan</surname>
              <given-names>G</given-names>
            </name>
            <name>
              <surname>Kostenis</surname>
              <given-names>E</given-names>
            </name>
          </person-group>
          <article-title>Heterotrimeric G-proteins: a short history</article-title>
          <source>Br J Pharmacol</source>
          <year>2006</year>
          <volume>147</volume>
          <fpage>S46</fpage>
          <lpage>S55</lpage>
          <pub-id pub-id-type="doi">10.1038/sj.bjp.0706405</pub-id>
        </citation>
        <citation citation-type="display-unstructured">Milligan G, Kostenis E (2006) Heterotrimeric G-proteins: a short history. Br J Pharmacol 147:S46&#x2013;S55 <pub-id pub-id-type="pmid">16402120</pub-id></citation>
      </ref>
      <ref id="CR50">
        <label>50.</label>
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Baldwin</surname>
              <given-names>SA</given-names>
            </name>
            <name>
              <surname>Mackey</surname>
              <given-names>JR</given-names>
            </name>
            <name>
              <surname>Cass</surname>
              <given-names>CE</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>Nucleoside transporters: molecular biology and implications for therapeutic development</article-title>
          <source>Mol Med Today</source>
          <year>1999</year>
          <volume>5</volume>
          <fpage>216</fpage>
          <lpage>224</lpage>
          <pub-id pub-id-type="doi">10.1016/S1357-4310(99)01459-8</pub-id>
        </citation>
        <citation citation-type="display-unstructured">Baldwin SA, Mackey JR, Cass CE et al (1999) Nucleoside transporters: molecular biology and implications for therapeutic development. Mol Med Today 5:216&#x2013;224 <pub-id pub-id-type="pmid">10322314</pub-id></citation>
      </ref>
      <ref id="CR51">
        <label>51.</label>
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Yao</surname>
              <given-names>R</given-names>
            </name>
            <name>
              <surname>Cooper</surname>
              <given-names>GM</given-names>
            </name>
          </person-group>
          <article-title>Requirement for phosphatidylinositol-3 kinase in the prevention of apoptosis by nerve growth factor</article-title>
          <source>Science</source>
          <year>1995</year>
          <volume>267</volume>
          <fpage>2003</fpage>
          <lpage>2006</lpage>
          <pub-id pub-id-type="doi">10.1126/science.7701324</pub-id>
        </citation>
        <citation citation-type="display-unstructured">Yao R, Cooper GM (1995) Requirement for phosphatidylinositol-3 kinase in the prevention of apoptosis by nerve growth factor. Science 267:2003&#x2013;2006 <pub-id pub-id-type="pmid">7701324</pub-id></citation>
      </ref>
      <ref id="CR52">
        <label>52.</label>
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Dudek</surname>
              <given-names>H</given-names>
            </name>
            <name>
              <surname>Datta</surname>
              <given-names>SR</given-names>
            </name>
            <name>
              <surname>Franke</surname>
              <given-names>TF</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>Regulation of neuronal survival by the serine-threonine protein kinase Akt</article-title>
          <source>Science</source>
          <year>1997</year>
          <volume>275</volume>
          <fpage>661</fpage>
          <lpage>665</lpage>
          <pub-id pub-id-type="doi">10.1126/science.275.5300.661</pub-id>
        </citation>
        <citation citation-type="display-unstructured">Dudek H, Datta SR, Franke TF et al (1997) Regulation of neuronal survival by the serine-threonine protein kinase Akt. Science 275:661&#x2013;665 <pub-id pub-id-type="pmid">9005851</pub-id></citation>
      </ref>
      <ref id="CR53">
        <label>53.</label>
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Franke</surname>
              <given-names>TF</given-names>
            </name>
            <name>
              <surname>Kaplan</surname>
              <given-names>DR</given-names>
            </name>
            <name>
              <surname>Cantley</surname>
              <given-names>LC</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>Direct regulation of the Akt proto-oncogene product by phosphatidylinositol-3,4-bisphosphate</article-title>
          <source>Science</source>
          <year>1997</year>
          <volume>275</volume>
          <fpage>665</fpage>
          <lpage>668</lpage>
          <pub-id pub-id-type="doi">10.1126/science.275.5300.665</pub-id>
        </citation>
        <citation citation-type="display-unstructured">Franke TF, Kaplan DR, Cantley LC et al (1997) Direct regulation of the Akt proto-oncogene product by phosphatidylinositol-3,4-bisphosphate. Science 275:665&#x2013;668 <pub-id pub-id-type="pmid">9005852</pub-id></citation>
      </ref>
      <ref id="CR54">
        <label>54.</label>
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Brunet</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>Datta</surname>
              <given-names>SR</given-names>
            </name>
            <name>
              <surname>Greenberg</surname>
              <given-names>ME</given-names>
            </name>
          </person-group>
          <article-title>Transcription-dependent and -independent control of neuronal survival by the PI3K-Akt signaling pathway</article-title>
          <source>Curr Opin Neurobiol</source>
          <year>2001</year>
          <volume>11</volume>
          <fpage>297</fpage>
          <lpage>305</lpage>
          <pub-id pub-id-type="doi">10.1016/S0959-4388(00)00211-7</pub-id>
        </citation>
        <citation citation-type="display-unstructured">Brunet A, Datta SR, Greenberg ME (2001) Transcription-dependent and -independent control of neuronal survival by the PI3K-Akt signaling pathway. Curr Opin Neurobiol 11:297&#x2013;305 <pub-id pub-id-type="pmid">11399427</pub-id></citation>
      </ref>
      <ref id="CR55">
        <label>55.</label>
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Bonni</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>Brunet</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>West</surname>
              <given-names>AE</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>Cell survival promoted by the Ras-MAPK signaling pathway by transcription-dependent and -independent mechanisms</article-title>
          <source>Science</source>
          <year>1999</year>
          <volume>286</volume>
          <fpage>1358</fpage>
          <lpage>1362</lpage>
          <pub-id pub-id-type="doi">10.1126/science.286.5443.1358</pub-id>
        </citation>
        <citation citation-type="display-unstructured">Bonni A, Brunet A, West AE et al (1999) Cell survival promoted by the Ras-MAPK signaling pathway by transcription-dependent and -independent mechanisms. Science 286:1358&#x2013;1362 <pub-id pub-id-type="pmid">10558990</pub-id></citation>
      </ref>
      <ref id="CR56">
        <label>56.</label>
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Hetman</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Gozdz</surname>
              <given-names>A</given-names>
            </name>
          </person-group>
          <article-title>Role of extracellular signal regulated kinases 1 and 2 in neuronal survival</article-title>
          <source>Eur J Biochem</source>
          <year>2004</year>
          <volume>271</volume>
          <fpage>2050</fpage>
          <lpage>2055</lpage>
          <pub-id pub-id-type="doi">10.1111/j.1432-1033.2004.04133.x</pub-id>
        </citation>
        <citation citation-type="display-unstructured">Hetman M, Gozdz A (2004) Role of extracellular signal regulated kinases 1 and 2 in neuronal survival. Eur J Biochem 271:2050&#x2013;2055 <pub-id pub-id-type="pmid">15153093</pub-id></citation>
      </ref>
      <ref id="CR57">
        <label>57.</label>
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Lopez-Ilasaca</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Crespo</surname>
              <given-names>P</given-names>
            </name>
            <name>
              <surname>Pellici</surname>
              <given-names>PG</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>Linkage of G protein-coupled receptors to the MAPK signaling pathway through PI 3-kinase gamma</article-title>
          <source>Science</source>
          <year>1997</year>
          <volume>275</volume>
          <fpage>394</fpage>
          <lpage>397</lpage>
          <pub-id pub-id-type="doi">10.1126/science.275.5298.394</pub-id>
        </citation>
        <citation citation-type="display-unstructured">Lopez-Ilasaca M, Crespo P, Pellici PG et al (1997) Linkage of G protein-coupled receptors to the MAPK signaling pathway through PI 3-kinase gamma. Science 275:394&#x2013;397 <pub-id pub-id-type="pmid">8994038</pub-id></citation>
      </ref>
      <ref id="CR58">
        <label>58.</label>
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Lopez-Ilasaca</surname>
              <given-names>M</given-names>
            </name>
          </person-group>
          <article-title>Signaling from G-protein-coupled receptors to mitogen-activated protein (MAP)-kinase cascades</article-title>
          <source>Biochem Pharmacol</source>
          <year>1998</year>
          <volume>56</volume>
          <fpage>269</fpage>
          <lpage>277</lpage>
          <pub-id pub-id-type="doi">10.1016/S0006-2952(98)00059-8</pub-id>
        </citation>
        <citation citation-type="display-unstructured">Lopez-Ilasaca M (1998) Signaling from G-protein-coupled receptors to mitogen-activated protein (MAP)-kinase cascades. Biochem Pharmacol 56:269&#x2013;277 <pub-id pub-id-type="pmid">9744561</pub-id></citation>
      </ref>
      <ref id="CR59">
        <label>59.</label>
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Marinissen</surname>
              <given-names>MJ</given-names>
            </name>
            <name>
              <surname>Gutkind</surname>
              <given-names>JS</given-names>
            </name>
          </person-group>
          <article-title>G-protein-coupled receptors and signaling networks: emerging paradigms</article-title>
          <source>Trends Pharmacol Sci</source>
          <year>2001</year>
          <volume>22</volume>
          <fpage>368</fpage>
          <lpage>376</lpage>
          <pub-id pub-id-type="doi">10.1016/S0165-6147(00)01678-3</pub-id>
        </citation>
        <citation citation-type="display-unstructured">Marinissen MJ, Gutkind JS (2001) G-protein-coupled receptors and signaling networks: emerging paradigms. Trends Pharmacol Sci 22:368&#x2013;376 <pub-id pub-id-type="pmid">11431032</pub-id></citation>
      </ref>
      <ref id="CR60">
        <label>60.</label>
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Wymann</surname>
              <given-names>MP</given-names>
            </name>
            <name>
              <surname>Zvelebil</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Laffargue</surname>
              <given-names>M</given-names>
            </name>
          </person-group>
          <article-title>Phosphoinositide 3-kinase signalling&#x2014;which way to target?</article-title>
          <source>Trends Pharmacol Sci</source>
          <year>2003</year>
          <volume>24</volume>
          <fpage>366</fpage>
          <lpage>376</lpage>
          <pub-id pub-id-type="doi">10.1016/S0165-6147(03)00163-9</pub-id>
        </citation>
        <citation citation-type="display-unstructured">Wymann MP, Zvelebil M, Laffargue M (2003) Phosphoinositide 3-kinase signalling&#x2014;which way to target? Trends Pharmacol Sci 24:366&#x2013;376 <pub-id pub-id-type="pmid">12871670</pub-id></citation>
      </ref>
      <ref id="CR61">
        <label>61.</label>
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Brazil</surname>
              <given-names>DP</given-names>
            </name>
            <name>
              <surname>Yang</surname>
              <given-names>ZZ</given-names>
            </name>
            <name>
              <surname>Hemmings</surname>
              <given-names>BA</given-names>
            </name>
          </person-group>
          <article-title>Advances in protein kinase B signalling: AKTion on multiple fronts</article-title>
          <source>Trends Biochem Sci</source>
          <year>2004</year>
          <volume>29</volume>
          <fpage>233</fpage>
          <lpage>242</lpage>
          <pub-id pub-id-type="doi">10.1016/j.tibs.2004.03.006</pub-id>
        </citation>
        <citation citation-type="display-unstructured">Brazil DP, Yang ZZ, Hemmings BA (2004) Advances in protein kinase B signalling: AKTion on multiple fronts. Trends Biochem Sci 29:233&#x2013;242 <pub-id pub-id-type="pmid">15130559</pub-id></citation>
      </ref>
      <ref id="CR62">
        <label>62.</label>
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Datta</surname>
              <given-names>SR</given-names>
            </name>
            <name>
              <surname>Dudek</surname>
              <given-names>H</given-names>
            </name>
            <name>
              <surname>Tao</surname>
              <given-names>X</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>Akt phosphorylation of BAD couples survival signals to the cell-intrinsic death machinery</article-title>
          <source>Cell</source>
          <year>1997</year>
          <volume>91</volume>
          <fpage>231</fpage>
          <lpage>241</lpage>
          <pub-id pub-id-type="doi">10.1016/S0092-8674(00)80405-5</pub-id>
        </citation>
        <citation citation-type="display-unstructured">Datta SR, Dudek H, Tao X et al (1997) Akt phosphorylation of BAD couples survival signals to the cell-intrinsic death machinery. Cell 91:231&#x2013;241 <pub-id pub-id-type="pmid">9346240</pub-id></citation>
      </ref>
      <ref id="CR63">
        <label>63.</label>
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Kennedy</surname>
              <given-names>SG</given-names>
            </name>
            <name>
              <surname>Kandel</surname>
              <given-names>ES</given-names>
            </name>
            <name>
              <surname>Cross</surname>
              <given-names>TK</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>Akt/Protein kinase B inhibits cell death by preventing the release of cytochrome c from mitochondria</article-title>
          <source>Mol Cell Biol</source>
          <year>1999</year>
          <volume>19</volume>
          <fpage>5800</fpage>
          <lpage>5810</lpage>
        </citation>
        <citation citation-type="display-unstructured">Kennedy SG, Kandel ES, Cross TK et al (1999) Akt/Protein kinase B inhibits cell death by preventing the release of cytochrome c from mitochondria. Mol Cell Biol 19:5800&#x2013;5810 <pub-id pub-id-type="pmid">10409766</pub-id></citation>
      </ref>
      <ref id="CR64">
        <label>64.</label>
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Zhou</surname>
              <given-names>H</given-names>
            </name>
            <name>
              <surname>Li</surname>
              <given-names>XM</given-names>
            </name>
            <name>
              <surname>Meinkoth</surname>
              <given-names>J</given-names>
            </name>
            <name>
              <surname>Pittman</surname>
              <given-names>RN</given-names>
            </name>
          </person-group>
          <article-title>Akt regulates cell survival and apoptosis at a postmitochondrial level</article-title>
          <source>J Cell Biol</source>
          <year>2000</year>
          <volume>151</volume>
          <fpage>483</fpage>
          <lpage>494</lpage>
          <pub-id pub-id-type="doi">10.1083/jcb.151.3.483</pub-id>
        </citation>
        <citation citation-type="display-unstructured">Zhou H, Li XM, Meinkoth J, Pittman RN (2000) Akt regulates cell survival and apoptosis at a postmitochondrial level. J Cell Biol 151:483&#x2013;494 <pub-id pub-id-type="pmid">11062251</pub-id></citation>
      </ref>
      <ref id="CR65">
        <label>65.</label>
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Xia</surname>
              <given-names>Z</given-names>
            </name>
            <name>
              <surname>Dickens</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Raingeaud</surname>
              <given-names>J</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>Opposing effects of ERK and JNK-p38 MAP kinases on apoptosis</article-title>
          <source>Science</source>
          <year>1995</year>
          <volume>270</volume>
          <fpage>1326</fpage>
          <lpage>1331</lpage>
          <pub-id pub-id-type="doi">10.1126/science.270.5240.1326</pub-id>
        </citation>
        <citation citation-type="display-unstructured">Xia Z, Dickens M, Raingeaud J et al (1995) Opposing effects of ERK and JNK-p38 MAP kinases on apoptosis. Science 270:1326&#x2013;1331 <pub-id pub-id-type="pmid">7481820</pub-id></citation>
      </ref>
      <ref id="CR66">
        <label>66.</label>
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Wada</surname>
              <given-names>T</given-names>
            </name>
            <name>
              <surname>Penninger</surname>
              <given-names>JM</given-names>
            </name>
          </person-group>
          <article-title>Mitogen-activated protein kinases in apoptosis regulation</article-title>
          <source>Oncogene</source>
          <year>2004</year>
          <volume>23</volume>
          <fpage>2838</fpage>
          <lpage>2849</lpage>
          <pub-id pub-id-type="doi">10.1038/sj.onc.1207556</pub-id>
        </citation>
        <citation citation-type="display-unstructured">Wada T, Penninger JM (2004) Mitogen-activated protein kinases in apoptosis regulation. Oncogene 23:2838&#x2013;2849 <pub-id pub-id-type="pmid">15077147</pub-id></citation>
      </ref>
      <ref id="CR67">
        <label>67.</label>
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Allan</surname>
              <given-names>LA</given-names>
            </name>
            <name>
              <surname>Morrice</surname>
              <given-names>N</given-names>
            </name>
            <name>
              <surname>Brady</surname>
              <given-names>S</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>Inhibition of caspase-9 through phosphorylation at Thr 125 by ERK MAPK</article-title>
          <source>Nat Cell Biol</source>
          <year>2003</year>
          <volume>5</volume>
          <fpage>647</fpage>
          <lpage>654</lpage>
          <pub-id pub-id-type="doi">10.1038/ncb1005</pub-id>
        </citation>
        <citation citation-type="display-unstructured">Allan LA, Morrice N, Brady S et al (2003) Inhibition of caspase-9 through phosphorylation at Thr 125 by ERK MAPK. Nat Cell Biol 5:647&#x2013;654 <pub-id pub-id-type="pmid">12792650</pub-id></citation>
      </ref>
      <ref id="CR68">
        <label>68.</label>
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Sato</surname>
              <given-names>S</given-names>
            </name>
            <name>
              <surname>Fujita</surname>
              <given-names>N</given-names>
            </name>
            <name>
              <surname>Tsuruo</surname>
              <given-names>T</given-names>
            </name>
          </person-group>
          <article-title>Involvement of 3-phosphoinositide-dependent protein kinase-1 in the MEK/MAPK signal transduction pathway</article-title>
          <source>J Biol Chem</source>
          <year>2004</year>
          <volume>279</volume>
          <fpage>33759</fpage>
          <lpage>33767</lpage>
          <pub-id pub-id-type="doi">10.1074/jbc.M402055200</pub-id>
        </citation>
        <citation citation-type="display-unstructured">Sato S, Fujita N, Tsuruo T (2004) Involvement of 3-phosphoinositide-dependent protein kinase-1 in the MEK/MAPK signal transduction pathway. J Biol Chem 279:33759&#x2013;33767 <pub-id pub-id-type="pmid">15175348</pub-id></citation>
      </ref>
      <ref id="CR69">
        <label>69.</label>
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Lee</surname>
              <given-names>CS</given-names>
            </name>
            <name>
              <surname>Han</surname>
              <given-names>ES</given-names>
            </name>
            <name>
              <surname>Jang</surname>
              <given-names>YY</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>Protective effect of harmalol and harmaline on MPTP neurotoxicity in the mouse and dopamine-induced damage of brain mitochondria and PC12 cells</article-title>
          <source>J Neurochem</source>
          <year>2000</year>
          <volume>75</volume>
          <fpage>521</fpage>
          <lpage>531</lpage>
          <pub-id pub-id-type="doi">10.1046/j.1471-4159.2000.0750521.x</pub-id>
        </citation>
        <citation citation-type="display-unstructured">Lee CS, Han ES, Jang YY et al (2000) Protective effect of harmalol and harmaline on MPTP neurotoxicity in the mouse and dopamine-induced damage of brain mitochondria and PC12 cells. J Neurochem 75:521&#x2013;531 <pub-id pub-id-type="pmid">10899927</pub-id></citation>
      </ref>
      <ref id="CR70">
        <label>70.</label>
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Maruyama</surname>
              <given-names>W</given-names>
            </name>
            <name>
              <surname>Akao</surname>
              <given-names>Y</given-names>
            </name>
            <name>
              <surname>Carrillo</surname>
              <given-names>MC</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>Neuroprotection by propargylamines in Parkinson&#x2019;s disease: suppression of apoptosis and induction of prosurvival genes</article-title>
          <source>Neurotoxicol Teratol</source>
          <year>2002</year>
          <volume>24</volume>
          <fpage>675</fpage>
          <lpage>682</lpage>
          <pub-id pub-id-type="doi">10.1016/S0892-0362(02)00221-0</pub-id>
        </citation>
        <citation citation-type="display-unstructured">Maruyama W, Akao Y, Carrillo MC et al (2002) Neuroprotection by propargylamines in Parkinson&#x2019;s disease: suppression of apoptosis and induction of prosurvival genes. Neurotoxicol Teratol 24:675&#x2013;682 <pub-id pub-id-type="pmid">12200198</pub-id></citation>
      </ref>
      <ref id="CR71">
        <label>71.</label>
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Sharma</surname>
              <given-names>SK</given-names>
            </name>
            <name>
              <surname>Carlson</surname>
              <given-names>EC</given-names>
            </name>
            <name>
              <surname>Ebadi</surname>
              <given-names>M</given-names>
            </name>
          </person-group>
          <article-title>Neuroprotective actions of Selegiline in inhibiting 1-methyl, 4-phenyl, pyridinium ion (MPP+)-induced apoptosis in SK-N-SH neurons</article-title>
          <source>J Neurocytol</source>
          <year>2003</year>
          <volume>32</volume>
          <fpage>329</fpage>
          <lpage>343</lpage>
          <pub-id pub-id-type="doi">10.1023/B:NEUR.0000011327.23739.1b</pub-id>
        </citation>
        <citation citation-type="display-unstructured">Sharma SK, Carlson EC, Ebadi M (2003) Neuroprotective actions of Selegiline in inhibiting 1-methyl, 4-phenyl, pyridinium ion (MPP+)-induced apoptosis in SK-N-SH neurons. J Neurocytol 32:329&#x2013;343 <pub-id pub-id-type="pmid">14724376</pub-id></citation>
      </ref>
      <ref id="CR72">
        <label>72.</label>
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Kitamura</surname>
              <given-names>Y</given-names>
            </name>
            <name>
              <surname>Kosaka</surname>
              <given-names>T</given-names>
            </name>
            <name>
              <surname>Kakimura</surname>
              <given-names>JI</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>Protective effects of the antiparkinsonian drugs talipexole and pramipexole against 1-methyl-4-phenylpyridinium-induced apoptotic death in human neuroblastoma SH-SY5Y cells</article-title>
          <source>Mol Pharmacol</source>
          <year>1998</year>
          <volume>54</volume>
          <fpage>1046</fpage>
          <lpage>1054</lpage>
        </citation>
        <citation citation-type="display-unstructured">Kitamura Y, Kosaka T, Kakimura JI et al (1998) Protective effects of the antiparkinsonian drugs talipexole and pramipexole against 1-methyl-4-phenylpyridinium-induced apoptotic death in human neuroblastoma SH-SY5Y cells. Mol Pharmacol 54:1046&#x2013;1054 <pub-id pub-id-type="pmid">9855633</pub-id></citation>
      </ref>
      <ref id="CR73">
        <label>73.</label>
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Wang</surname>
              <given-names>X-J</given-names>
            </name>
            <name>
              <surname>Xu</surname>
              <given-names>J-X</given-names>
            </name>
          </person-group>
          <article-title>Salvianic acid A protects human neuroblastoma cells SH-SY5Y cells against MPP<sup>+</sup>-induced cytotoxicity</article-title>
          <source>Neurosci Res</source>
          <year>2005</year>
          <volume>51</volume>
          <fpage>129</fpage>
          <lpage>138</lpage>
          <pub-id pub-id-type="doi">10.1016/j.neures.2004.10.001</pub-id>
        </citation>
        <citation citation-type="display-unstructured">Wang X-J, Xu J-X (2005) Salvianic acid A protects human neuroblastoma cells SH-SY5Y cells against MPP+-induced cytotoxicity. Neurosci Res 51:129&#x2013;138 <pub-id pub-id-type="pmid">15681030</pub-id></citation>
      </ref>
      <ref id="CR74">
        <label>74.</label>
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Bernstein</surname>
              <given-names>C</given-names>
            </name>
            <name>
              <surname>Bernstein</surname>
              <given-names>H</given-names>
            </name>
            <name>
              <surname>Payne</surname>
              <given-names>CM</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>DNA repair/pro-apoptotic dual-role proteins in five major DNA repair pathways: fail-safe protection against carcinogenesis</article-title>
          <source>Mutat Res</source>
          <year>2002</year>
          <volume>511</volume>
          <fpage>145</fpage>
          <lpage>178</lpage>
          <pub-id pub-id-type="doi">10.1016/S1383-5742(02)00009-1</pub-id>
        </citation>
        <citation citation-type="display-unstructured">Bernstein C, Bernstein H, Payne CM et al (2002) DNA repair/pro-apoptotic dual-role proteins in five major DNA repair pathways: fail-safe protection against carcinogenesis. Mutat Res 511:145&#x2013;178 <pub-id pub-id-type="pmid">12052432</pub-id></citation>
      </ref>
      <ref id="CR75">
        <label>75.</label>
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Subba Rao</surname>
              <given-names>S</given-names>
            </name>
          </person-group>
          <article-title>Mechanisms of disease: DNA repair defects and neurological disease</article-title>
          <source>Nat Clin Pract Neurol</source>
          <year>2007</year>
          <volume>3</volume>
          <fpage>162</fpage>
          <lpage>172</lpage>
          <pub-id pub-id-type="doi">10.1038/ncpneuro0448</pub-id>
        </citation>
        <citation citation-type="display-unstructured">Subba Rao K (2007) Mechanisms of disease: DNA repair defects and neurological disease. Nat Clin Pract Neurol 3:162&#x2013;172 <pub-id pub-id-type="pmid">17342192</pub-id></citation>
      </ref>
      <ref id="CR76">
        <label>76.</label>
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Wang</surname>
              <given-names>H</given-names>
            </name>
            <name>
              <surname>Shimoji</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Yu</surname>
              <given-names>SW</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>Apoptosis inducing factor and PARP-mediated injury in the MPTP mouse model of Parkinson&#x2019;s disease</article-title>
          <source>Ann N Y Acad Sci</source>
          <year>2003</year>
          <volume>991</volume>
          <fpage>132</fpage>
          <lpage>139</lpage>
        </citation>
        <citation citation-type="display-unstructured">Wang H, Shimoji M, Yu SW et al (2003) Apoptosis inducing factor and PARP-mediated injury in the MPTP mouse model of Parkinson&#x2019;s disease. Ann N Y Acad Sci 991:132&#x2013;139 <pub-id pub-id-type="pmid">12846982</pub-id></citation>
      </ref>
      <ref id="CR77">
        <label>77.</label>
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Krantic</surname>
              <given-names>S</given-names>
            </name>
            <name>
              <surname>Mechawar</surname>
              <given-names>N</given-names>
            </name>
            <name>
              <surname>Reix</surname>
              <given-names>S</given-names>
            </name>
          </person-group>
          <article-title>Molecular basis of programmed cell death involved in neurodegeneration</article-title>
          <source>Trends Neurosci</source>
          <year>2005</year>
          <volume>28</volume>
          <fpage>670</fpage>
          <lpage>676</lpage>
        </citation>
        <citation citation-type="display-unstructured">Krantic S, Mechawar N, Reix S (2005) Molecular basis of programmed cell death involved in neurodegeneration. Trends Neurosci 28:670&#x2013;676 <pub-id pub-id-type="pmid">16216345</pub-id></citation>
      </ref>
      <ref id="CR78">
        <label>78.</label>
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Abraham</surname>
              <given-names>MC</given-names>
            </name>
            <name>
              <surname>Shaham</surname>
              <given-names>S</given-names>
            </name>
          </person-group>
          <article-title>Death without caspases, caspases without death</article-title>
          <source>Trends Cell Biol</source>
          <year>2004</year>
          <volume>14</volume>
          <fpage>184</fpage>
          <lpage>193</lpage>
          <pub-id pub-id-type="doi">10.1016/j.tcb.2004.03.002</pub-id>
        </citation>
        <citation citation-type="display-unstructured">Abraham MC, Shaham S (2004) Death without caspases, caspases without death. Trends Cell Biol 14:184&#x2013;193 <pub-id pub-id-type="pmid">15066636</pub-id></citation>
      </ref>
      <ref id="CR79">
        <label>79.</label>
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Chipuk</surname>
              <given-names>JE</given-names>
            </name>
            <name>
              <surname>Green</surname>
              <given-names>DR</given-names>
            </name>
          </person-group>
          <article-title>Do inducers of apoptosis trigger caspase-independent cell death?</article-title>
          <source>Nat Rev Mol Cell Biol</source>
          <year>2005</year>
          <volume>6</volume>
          <fpage>268</fpage>
          <lpage>275</lpage>
          <pub-id pub-id-type="doi">10.1038/nrm1573</pub-id>
        </citation>
        <citation citation-type="display-unstructured">Chipuk JE, Green DR (2005) Do inducers of apoptosis trigger caspase-independent cell death? Nat Rev Mol Cell Biol 6:268&#x2013;275 <pub-id pub-id-type="pmid">15714200</pub-id></citation>
      </ref>
      <ref id="CR80">
        <label>80.</label>
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Kroemer</surname>
              <given-names>G</given-names>
            </name>
            <name>
              <surname>Martin</surname>
              <given-names>SJ</given-names>
            </name>
          </person-group>
          <article-title>Caspase-independent cell death</article-title>
          <source>Nat Med</source>
          <year>2005</year>
          <volume>11</volume>
          <fpage>725</fpage>
          <lpage>730</lpage>
          <pub-id pub-id-type="doi">10.1038/nm1263</pub-id>
        </citation>
        <citation citation-type="display-unstructured">Kroemer G, Martin SJ (2005) Caspase-independent cell death. Nat Med 11:725&#x2013;730 <pub-id pub-id-type="pmid">16015365</pub-id></citation>
      </ref>
    </ref-list>
  </back>
</article>
</pmc-articleset>